0001279569-17-002379.txt : 20171212 0001279569-17-002379.hdr.sgml : 20171212 20171212123028 ACCESSION NUMBER: 0001279569-17-002379 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20171212 FILED AS OF DATE: 20171212 DATE AS OF CHANGE: 20171212 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cardiome Pharma Corp CENTRAL INDEX KEY: 0001036141 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-29338 FILM NUMBER: 171251302 BUSINESS ADDRESS: STREET 1: 6TH FLOOR STREET 2: 1441 CREEKSIDE DRIVE CITY: VANCOUVER STATE: A1 ZIP: V6J 4S7 BUSINESS PHONE: 1-604-677-6905 MAIL ADDRESS: STREET 1: 6TH FLOOR STREET 2: 1441 CREEKSIDE DRIVE CITY: VANCOUVER STATE: A1 ZIP: V6J 4S7 FORMER COMPANY: FORMER CONFORMED NAME: CARDIOME PHARMA CORP DATE OF NAME CHANGE: 20000407 6-K 1 cardiome6k.htm FORM 6-K

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13A-16 or 15d-16 of

The Securities Exchange Act of 1934

 

For the month of December 2017

 

COMMISSION FILE Number. 000-29338

 

CARDIOME PHARMA CORP.

 

(Translation of registrant’s name into English)

 

1441 Creekside Drive, 6th floor

Vancouver, British Columbia, V6J 4S7, CANADA

 

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

 

Form 20-F ☐ Form 40-F

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

  

 

 

 
 

 

 

DOCUMENTS INCLUDED AS PART OF THIS REPORT

 

Exhibit   Description
     
99.1   News Release dated December 12, 2017 - Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia

  

 

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  CARDIOME PHARMA CORP.
  (Registrant)
     
Date: December 12, 2017 By: /s/ Justin Renz
    Name: Justin Renz
    Title: Chief Financial Officer

 

 

 


EX-99.1 2 ex991.htm NEWS RELEASE DATED DECEMBER 12, 2017

Exhibit 99.1

 

 

 

Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia

NASDAQ:CRME TSX:COM

VANCOUVER, Dec. 12, 2017 /CNW/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today announced that its affiliate Correvio has entered into an exclusive license and distribution agreement with ZAO Firma Euroservice that will advance Aggrastat® (tirofiban hydrochloride) toward commercialization in Russia. Aggrastat is indicated for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) and is currently marketed in over 60 countries worldwide.

Under the terms of the license agreement, ZAO will be responsible for obtaining regulatory approvals for Aggrastat from Russia's Ministry of Health, then executing the commercial launch and subsequent sale and marketing of Aggrastat in the territory. Under the agreement, Cardiome and ZAO have agreed to certain minimum annual purchase requirements. Additional terms of the agreement were not disclosed.

"ZAO Firma Euroservice has a solid track record of regulatory and commercial expertise, obtaining necessary drug distribution approvals and the subsequent delivering of high-quality medications to hospitals and customers throughout Russia," said Hugues Sachot, Cardiome's Chief Commercial Officer. "Aggrastat is currently marketed in over 60 countries worldwide, and we're pleased to be adding Russia as a new territory for distribution of this important medication."

Mikhail Lazarev, Director, Regulatory Affairs at ZAO Firma Euroservice commented, "The addition of Aggrastat to our hospital products line underscores our commitment to bringing high-quality products into the hands of the physicians and patients who need them. We look forward to filing a timely registration package for Aggrastat in one year time, and obtaining the required authorizations to advance this high-value product toward the market."

About Acute Coronary Syndromes

Acute Coronary Syndromes (ACS) is a term that refers to a variety of conditions consistent with acute myocardial ischemia and/or infarction that are usually due to an abrupt reduction in coronary blood flow1. The ACS spectrum includes patients with ST-elevation myocardial infarction (STEMI) and non-ST–elevation ACS (NSTE-ACS), which is comprised of non-STEMI (NSTEMI) and unstable angina. The Thrombus (i.e. blood clot that forms inside a blood vessel or chamber of the heart) formation reduce blood flow in the affected coronary artery and cause ischemic chest pain1.  Research from Datamonitor estimates that in 2013, >880,000 persons in the US experienced an ACS event, while in the major five EU markets, this figure was >650,000.2 Furthermore, the number of ACS incidences is expected to grow nearly 40% by 2033.2 Approximately 70,000 acute myocardial infarctions occur each year in Canada and some 19,000 Canadians die from this condition3.

More About AGGRASTAT®

AGGRASTAT® (tirofiban hydrochloride, or HCl) is an intravenous (IV) non-peptidal antagonist of the glycoprotein (GP) IIb/IIIa receptor, an important platelet surface receptor involved in platelet aggregation. AGGRASTAT, in combination with heparin and acetylsalicylic acid (ASA), is currently approved in Canada for the management of patients with unstable angina or non-Q-wave myocardial infarction, including patients who may subsequently undergo PCI to decrease the rate of refractory ischemic conditions, new myocardial infarction and death.  By blocking fibrinogen from binding to the GP IIb/IIIa receptor, AGGRASTAT prevents the crosslinking of platelets, which is the basis for platelet aggregation.  AGGRASTAT is commercialized in 60 countries worldwide, either by Cardiome or via its extensive distributor and partner network. Cardiome acquired Canadian AGGRASTAT® commercialization rights through its acquisition of Correvio LLC in November 2013.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a revenue-generating, specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients.  With a commercial presence and distribution network covering over 60 countries worldwide, Cardiome develops, acquires and commercializes brands for the in-hospital, acute care market segment.  The Company's portfolio of approved and marketed brands includes: Xydalba™ (dalbavancin hydrochloride), for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Zevtera®/Mabelio® (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community- and hospital-acquired pneumonia (CAP, HAP); Brinavess® (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm; Aggrastat® (tirofiban hydrochloride) for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome, and Esmocard® and Esmocard Lyo® (esmolol hydrochloride), a short-acting beta-blocker used to control rapid heart rate in a number of cardiovascular indications. Cardiome's pipeline of product candidates includes Trevyent®, a drug device combination that is designed to deliver Remodulin® (treprostinil) the world's leading treatment for pulmonary arterial hypertension.

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.

References

1. Amsterdam EA et al. 2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64:e139–228.
2. Datamonitor. Acute Coronary Syndrome: Epidemiology. October 2014.
3. Fitchett DH et al. Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 1: Non-ST–Segment Elevation ACS Can J Cardiol 2011; 27:S387–S401

Forward-Looking Statement Disclaimer

Certain statements in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Forward- looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for 2017 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research and development and product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such known risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions in the United States, Canada, Europe, and the other regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; availability of financial reimbursement coverage from governmental and third-party payers for products and related treatments; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to expand commercialization activities; and any other factors that may affect our performance. In addition, our business is subject to certain operating risks that may cause any results expressed or implied by the forward-looking statements in this presentation to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in our business strategy or development plans; intellectual property matters, including the unenforceability or loss of patent protection resulting from third-party challenges to our patents; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; and the availability of capital to finance our activities. These and other risks are described in the Form 40F and associated documents filed March 29, 2017 (see for example, "Risk Factors" in the Annual Information Form for the year ended December 31, 2016), in the Form 6-K filed November 14, 2017, and in our other filings with the Securities and Exchange Commission ("SEC") available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

Cardiome® and the Cardiome Logo are the proprietary trademarks of Cardiome Pharma Corp.
Aggrastat® and Brinavess® are trademarks owned by Cardiome and its affiliates worldwide.
Xydalba® is a trademark of Durata Therapeutics Holding C.V., and used under license.
Zevtera® and Mabelio® are trademarks owned by Basilea Pharmaceutica International Ltd., and used under license.
Esmocard® and Esmocard Lyo® are trademarks owned by Orpha-Devel Handels und Vertriebs GmbH, and used under license.
Trevyent® is a trademark of SteadyMed and used under license.
All other trademarks are the property of their respective owners.

SOURCE Cardiome Pharma Corp.

View original content: http://www.newswire.ca/en/releases/archive/December2017/12/c4650.html

%CIK: 0001036141

For further information: Justin Renz, CFO, Cardiome Pharma Corp., 604.677.6905 ext. 128, 800.330.9928, jrenz@cardiome.com; Argot Partners, Michelle Carroll/Sean Augustine-Obi, 212.600.1902, michelle@argotpartners.com, sean@argotpartners.com

CO: Cardiome Pharma Corp.

CNW 08:00e 12-DEC-17

EX-99.1 3 ex991.pdf PRINTER FRIENDLY COPY begin 644 ex991.pdf M)5!$1BTQ+C4-)>+CS],-"C(R(# @;V)J#3P\+TQI;F5AJY39F8-AV@8&!4?NLT)Z+VF<9.AHX.L $3!8)\$,Q T,, S^C'F\#VPWM M )^$60=-FX)9%G ^X#NQJ(%!:-6$&&"(3/* 80 M8 /=1JZ#0IE;F1S=')E86T-96YD;V)J#3(S(# @;V)J#3P\+TUE=&%D871A M(#$Q(# @4B]086=E3&%B96QS(#$X(# @4B]086=E%LP(# @-C$R(#%LP(# @-C$R(#NB;M)=MC9T:$,* MRN%N/&;?7NQY:C-+BO-44)I.,:\KBW?+I: L>(>BHA2=&%#XSO*VJ=>IL2MV M.YNSI7FQ;%%F6S-]8-]O'O\V:PJS* 6HN',8CU=L,9V>9:W9@'*Q']#DYA9^ M9$5K4+@"P=))?TRO@/_!)5ON=^8(E]6[3C\>H^^D79O*0A1P-EW,$ RHT &= M9KL+DV^?+' V,YW52*+9O,BV+6A7YME9_;(:!5S!2 D%0FH.@LOPP6GG>6$D MJ*YPNKC.2L,N;ZYGEQ=?IEF1/S8Y6U@4UI-J6QC,E%I3_H5O!YE<*'63[VS= M.+A4.EW_'(6P[UMT7E0_:FI)LS%-7FU/%AL$GMO]*;LSV[RUS?YDLJD?S2E+ MGW>[PI14%\=98(1E?;Z8764[YIW8[![+X?PG)$0E*BE]?K2$$UW)@##+(W)V MOU(KB;W " &%B2'@T<.[972-WF38.]2V*R0KS9A]J];U!LLY(!M='+)30FQ8 M_6>5HY$!V[^-AV=U<7F:NGTJ6V,73^QZ[HIL\)=W7>((NSU M6X00X?^@Q"\R'GIWGU>3JLT/YWG>M';ZE#6@Y'\FW#7Q,NLM1*2/#6^>S=)W MOA]UOK%/[0K7 ]Y^2*.4@LXBX,>??[Q,5D//2,K^GWYA&$&('ZPHHD^"BA-G M0[<)_82"SR3A]PG[@S9_]Z/;#O6X3FD+V$BQ7$+>DX3UXEOGM\N M,_+0Z^)>]KO@_=U>"''0^?WA[G;(*+<1_/7[L!D#G%Z.WJC1HQK6[Q#ULG9? M^H\\%)&\.D^_)TG\@4T).6[*OP(, #6;98-"F5N9'-TX'PP$$;*"N06H2M6F\Q<@\+50GOTNQX4K@D[Z0&IY4PE:_C^/^M12J:'TD<[>:: MM=/UQ9R77EBV(@QMO6C8E)>UT&SY8H1BJ\OLM-T&-H%*&K9.WZ:4$+K9O(4/ MN5G;Q6*#-\'8?#F#>(525-[$[=N&UDLD^H7)Z,0TG7$K'%MWW:);XJ0&%P)A MQ6DQT-)F/%O%E,6B6[=SRE#$3($/O$2P_.T+5Q9-!_%"CLUX:5CNSA5BYJ)- M=,(TP'R90!7J! 42254FE?I55&Q]N=G,IYPD\RJ'6J<55Y5!M?JHUKCUFNJ$ M;NA %_S<[X;]Z7D\3*#M=_UM/X&+<1AYZ9!ERY7&O7TC2>"%QP,B:@HH/0$M M$>I/)$1!5EF07M05(B!E?%J;Q]$AOC%IRK*>XY^('6X?]]L1/M+%-7O *10Z M;'O(:?OTZ?"$E@X";E[TJI->4]XZF05J!G$[..,.W?S,"0D;D>(35EP>+C4_ MDTDEE#>A,C@^Y<0AEN6L/CH_DI,;_.:J07Z4KV=/#WUNO\T%0_+' MT[_CACXW@6$?)^?\)QK>)YB7QJ@IQ>[VP^DXWD+*3@FX-/@KP "5VAK;#0IE M;F1S=')E86T-96YD;V)J#3(X(# @;V)J#3P\+T9I;'1EX>2F^\SY>K\/&/T+N5,?#=!:=*CF[N31,20K9J(;?A(1UCFGHT^#% MC\-384I56Z;9X2-!FU=H0]#L$I=;2&YD?EX1L^/+>R'+4BO#4_0.^4K^6UAT M,2&-YFZ:XCKUP"!+F^,NQ%6ING[@JEZY*N)RB86T,'JL<;O!MPN1##R/FV0GN!3^'7/^!6FL>_-HG[ ^H!P=Q\03..5Z/,84>K@8C MWX"B$AIP]B%B$@#R? , !R8C^ T*96YDH1R\<@/10%B@*M>VF3@RS3,1&)=$DJ M;GZC7]PEEW84H!=)^YJ=G5U54C0-E+#]N"I$65:P'59"QO=Y]8O-(R\:4;'> M 2]DR=2+,H%5Z!CH:-;,H,G@A%F8S25& @4TI2N30MF9BC<,SCF:,8\) MI!_F;*L$1*T'ZZSI>=&AWZ%GPUZYC,''[>=54:4Q"BED+'&%C/&F',X+DI0U>A)A3#U[CFUE*UH MUV_"E9O<+G[$?@IGD+603"&L ?NB7$1&B-L2!CN;X+3R<+9NW)_U7@D:A&!1 MG3HB"]E=\'Z8O7(0CI$SHB@(*N(ARXF&=3HXWHF7VA>S1PX$<>$HMHR#<11XU\H@^?%*H0.DSC.=BS0)]XQZK MKD2;@-P";KJ$OB%KM&?O-17]35D>ON#D/KA77L=XW-,GE1(RO7"\P?D Y MZ_=RXB_AYYTGQ-]SYAG 9_JY_S4YK7[J%P2>$RG*6U"WA_>;>*+L_ZN_B1+K M=*=K9M[&#LM)Z:GQ@EYY%7L(P%]FJ6)>/I9GPI?-JZ0.)>%*LOMEEG% _^"3 5S%$]@T*96YDY%&FN6]>3.SOUGMWZPJ4==U!_MA)6I)QN/J*U.SAELN:]&RZT\PJC.O\*-C MAE=-MQ%;IGA%KWN^P[_>E"^C(3H8C(_*SC#9V4YI C7/21T!J[%3\OS;_F;5 M2+'NH8;]NP+?7N#; C^,*ACPO-HB <-;Q'A(UIO)S#$((#+L6FL;K9NQ=#1^ M"N#N(([(!WEP22F0L:H"5DDANPN@7/K-1N[WWALS8=V6TN?(*S+@T2"'/O?= M(!.8W<6C;3'"<"R&PV2Q9L%HD6%KJ##E MB4#IM-LW3XZQ9U_8!%UJ0?(9.A MX'WR+AA_MLN?P:#Z 10$=RS!2X[F5:84EQ*%$,K'UZ)A6(!>F-_A=*5$.W%Z(KR4./>.18<@LA,]>^(MNR2TBT@3ZN>*G\,D)D_VJ( MM' M1(L%ZG3R[KP$J&,H9)I:X)6\[&YW8?'7Z<310$B'8![2\^&TB#]'T(:$;'!: MEB:X96?C"V5<6+=$W^&ZX>=HE]#B'GF%S^H!K\GBV!OR/)7$1:9,[;\B]1>1 M)J/MH*B_0,PL M+XI2P;%=Y86BRWWU2WR6V2Y7XBRS$@\KLVV^$4:JO!(]L-,EYY".Q[R_=69O7_^!SPN1#O!SH0]'225=X(+[,&K80R!<;$L]S3C4DF M*J01T,Z8325Y;T8.7JC?(AX,;"9$_VI"?"B%Z8#1QM06N!NC&:X"]@6TCA_G MA< OPYG@[OPE&=V=7[L$9M:RB;-_V[^(&LM M#%PO1F.#2N4U%1D&^#B\RJR:L=%'!\6!7,ODGDR%SAP,I")(3>Q<-#9Z?@[@PPF,ZVFISYWTB1)0XI* $./2$WHE\*\YBD<*PZ,7(V_(QU'A[AZQ(W, E\F;V;XKXK+L;? M+-?92E0="HJ"!6>P;!4'=VMX/YY-4DH!6*7:+8,LED^VX$^6-+$LYH#?3Q-; MH@]#3T$'4HZ;/9RQH+A^K*E.ZX]PVP5NF^"N-N@+7+WKYC9,<+$CUK3)MP+F ML3-^:IU'R1-B@L.J$]H'L*+9)S#LTH=,GL6$LXVQ ME8@/&_P/X6LFG^&? , ?=XF,@T*96YDXQ^<)M^?,9:KI>C"#-8%#V$<8#2NG\'OV#F-,BMR5<5K*S'C#54(VUGC M9OFG?5T06@GYG;R^D=>1'(A#&)G5:BU<#R<3[."0\#)Z<,/0$P]E&W%$+OQ3 M +\H4 N,%PUE#M[O8>>GBYEZUHP%,'L6Z>_UHP*MDX)F'15@73NY5%K8@W4? M4N-9 2BH6%=H!7L<,+L6!P2FU!4S=8.!B2^A!CJ6[EFJ7XLYQ*2)R6"]P\(8 MIN/?O=2<)ON#[4B2E'@.10S84+&K="SQW.#ISBQ5*4)2%T,!QP7>)4SN\%66 M^B$W'D,4 5Q@);Y#C.$(_'N(=JK&/=I"LV#,6_'D?)[MLXL3:)B6!M!^6^34 M[SSVVIS#Z"?[ETHJA*'&S( #,/V7<=T0P\AB9Q@MDN9BC%M4JO7R:8M6<89L M$&[V90[GX6EI5[BT"$P+P8MZ3!LV[8>@_C'F2]N6@,NPPRUA>-RN,BU)41)! MEBQBV&!ME7BGCE3"GX.LL.L0HYVLL?H4&]B!'YSQ$C&QSS4/E6QGHG=E+\YF M>W5].G.4^@$RWW1642@LE M/=05=@>VM,:L@WT4X/D+4-(S8Z@9WL0FP6VI>UJ\2; QBP^]Y'<"-^9$DV[? MPF/486@_.3X-7!1^-%;5TT +*@G^"S 1O$AM@T*96YD 0=2(+E8 MQI4?R?>F6RUFQ@# MN5D?TIV%X.@YN@XFT"00EN>*5$U:EA#M1-]X!IH=;,M6CPC=)#@^&F^HT&Z= MOP4$8PSBO,S;;0UA,'?MUM"@8; \?"-F9[&K,@56*3_,V@-XFS9B8! Z+DH/ M0EQ&YUJXCNXNJS^'0D#Y@TU<84!533(:+\R.<:2C&Q3\## M)#BK(X4GI6NILJ1 05629-5W,B.M/3V?8+FQT?@G4B9% MRA2?&][$44S(F;^-_MO6]V!G=RR3%_$1 MYQ=3(^?;-1S'"%KO&M@U(I"K=Y.=H43\X2L:B@MWD.JR>)1[E/AQI F]T#C. MXE1]_4'7B$KZ)E&ON3A+&0>%>EPH+>NL.E7_@DG+FB&=U]HK 6>'&UO@-6$Y MG_J"114M=B*>GEF/1F?F78VT_0VV/YWE)[CW0]/#0*L[W<(ZS\/2M>"NU#FX MU(Z4<;YOM2_]2#/W-/F%:;Z\\N-DYXD6FL-EEK2]C%];(_L9_#K]T MM,N, 0.1N1$:JK[#W^RFR[; 60RZTX@&_@LP !!2*0@-"F5N9'-TI7HIB5?>=/]QBO M,-SC!MO-;S#&-*\PB59V?!$_^T?62>,*P=[79(8#9()UN@;P4'C^A'4-=XA) MH)8-AYV@,DK6"!5*;$X:W(5(M'CH&&Y^?@H)XD@Z MR"%U4K#2#K2=;&RNKJ5I2O6^Y?94V9DB4]+(3I'1 MKZ(R=(0U^#3<\E:R_43V#8\S7/SFY[A,6TQ DB=:4UC+;:"5Q/O?4\3S*>[O M3]!5TW*T0O- F%S"1Y'-.J<>J N>0UKCLAX;%)ASA?]3SWXSA F8ME8ZUX!U M&F;6ZAW<,VBU(G#FW_^5HF^P9)JND:TI]V2<= 1;E$U;4Q6=MH9A9A\^SPB7 MR+[0!_\$& "]_-(%#0IE;F1S=')E86T-96YD;V)J#3,U(# @;V)J#3P\+T%L M=&5R;F%T92]$979I8V521T(O1FEL=&5R+T9L871E1&5C;V1E+TQE;F=T:" R M-3DW+TX@,SX^J'-,-(9>I,N,(#T+B = M!%$89@88R@###$ULB*A 1!$1 460H( !HZ%(K(AB(2BH8 ]($%!B,(JHJ&1& MUDI\>7GOY>7WQ[W?VF?O<_?9>Y^U+@ D3Q\N+P66 B"9)^ '>CC35X5'T+'] M 9X@ &F #!9Z:F^0>[!0"0O-Q=ZNL@)_(O># %(_+YEZ.E/IX/_3]*L5+X M ,A?Q.9L3CI+Q/DB3LH4I(KM,R*FQB2*&4:)F2]*4,1R8HY;Y*6??1;94!&;B)C$#PYT$?%R '"DN"\XY@L6<+($XD.YI*1F\[EQ\0*Z+DN/ M;FIMS:![[M(KT*^-PSB-;WA^VO_%+J &#,BFJSZP];S'X .K8"('?_ M#YOF(0 D17UKO_'%>6CB>8D7"%)MC(TS,S.-N!R6D;B@O^M_.OP-??$](_%V MOY>'[LJ)90J3!'1QW5@I22E"/CT]E?^IB?\P[$]:G&N1*/6? #7*"$C=H +DYSZ HA ! M$GE0W/7?^^:##P7BFQ>F.K$X]Y\%_?NN<(GXD,X 9P\QBL5AYK '6#NN'96(%V +L?NPQ[#GL('8<^Q9'Q*GBS'#NN @< M#Y>'*\$AX1202U8G6Q BE[B)6$$\3KQ"'"6^(\F0]$DNI$B2D+23 M=(1TGG2/](I,)FN3'DDN58R1[)<\J3D#LHERC@50]6A>E$3 MJ$74;ZC]U!E9&=EELJ&R6;)5LF=D1V@(39OF14NBE=!.T(9H[YGR;O*)\KOE.^0?*: 4]!4"%#(5#BI< M4IA6I"K:*K(4"Q5/*-Y7@I7TE0*5UBD=5NI3FE564?903E7>KWQ1>5J%IN*H MDJ!2IG)694J5HFJORE4M4SVG^HPN2W>B)]$KZ#WT&34E-4\UH5JM6K_:O+J. M>HAZGGJK^B,-@@9#(U:C3*-;8T935=-7,U>S6?.^%EZ+H16OM4^K5VM.6T<[ M3'N;=H?VI(ZYM/8P>0R]1[X#>37U8WT(_7K]* M_X8!;&!IP#4X8#"P%+W4>BEO:=W284.2H9-AAF&SX:@1SJ/U:>MW-I8V IL3-K_8&MHFVC;93B[76/MC]D M/^*@YL!TJ'-XXJCAR'9L<)QPTG-*<#KF],+9Q)GOW.8\YV+CLM[EO"OBZN%: MZ-KO)N,6XE;I]MA=W3W.O=E]QL/"8YW'>4^TI[?G;L]A+V4OEE>CU\P*JQ7K M5_1XD[R#O"N]G_CH^_!]NGQAWQ6^>WP?KM1:R5O9X0?\O/SV^#WRU_%/\_\^ M !/@'U 5\#30-# WL#>($A05U!3T)M@YN"3X08ANB#"D.U0R-#*T,70NS#6L M-&QDE?&J]:NNARN$<\,[([ 1H1$-$;.KW5;O73T>:1%9$#FT1F=-UIJK:Q76 M)JT]$R49Q8PZ&8V.#HMNBO[ ]&/6,6=CO&*J8V98+JQ]K.=L1W89>XICQRGE M3,3:Q9;&3L;9Q>V)FXIWB"^/G^:Z<"NY+Q,\$VH2YA+]$H\D+B2%);4FXY*C MDT_Q9'B)O)X4E92LE(%4@]2"U)$TF[2]:3-\;WY#.I2^)KU30!7]3/4)=85; MA:,9]AE5&6\S0S-/9DEG\;+ZLO6S=V1/Y+CG?+T.M8ZUKCM7+7=S[NAZI_6U M&Z -,1NZ-VILS-\XOLECT]'-A,V)FW_(,\DKS7N])6Q+5[YR_J;\L:T>6YL+ M) KX!WSWM9?2RPK+7>Z/V7BU?5EZSC[!/ MN&^DPJ>B<[_F_EW[/U3&5]ZI5'\8-#0H-10T?C_".C!P-/-K3:-78V*34 M5-(,-PN;IXY%'KOYC>LWG2V&+;6MM-:BX^"X\/BS;Z._'3KA?:+[).-DRW=: MWU6W4=H*VZ'V[/:9COB.D<[PSH%3*TYU=]EVM7UO]/V1TVJGJ\[(GBDY2SB; M?W;A7,ZYV?.IYZ\+UVY['[Y8J]3[[DK=E=. M7[6Y>NH:XUK'=N;70/+!\X..@Q>N.5Z MZ_)MK]O7[ZR\,S 4,G1W.')XY"[[[N2]I'LO[V?$CJ4?ECY4> MU_VH]V/KB.7(F5'7T;XG04\>C+'&GO^4_M.'\?RGY*?E$ZH3C9-FDZ>GW*=N M/EO];/QYZO/YZ8*?I7^N?J'[XKM?''_IFUDU,_Z2_W+AU^)7\J^.O%[VNGO6 M?_;QF^0W\W.%;^7?'GW'>-?[/NS]Q'SF!^R'BH]Z'[L^>7]ZN)"\L/"; , M]X3S^PT*96YDFL P@("]@6$4C(+!#P " M# O4@$8#0IE;F1S=')E86T-96YD;V)J#3,W(# @;V)J#3P\+T9I;'1ER+ M+!%<(B#" "XL:E2$(!5*@T[02K N2%%1K%);7.K[KVLM*KA66R&9^_Z><\^= M3(9%^FD+?#GG//?<<\_^/&<94HBH*5601KW'Y_;J4WFD_RE(G@/^HF5+W(<6 MOM>/2.E 9#Q7NG#FO-O^JEU/Y'B/J%G*S+DWE]ZZ]/VWB+8C?DQI64E!\8\O M.&-(B3^-]_N70=!L?X?91 DZPIW+YBTI_\O7+WZ$<%>BXL?G+B@JH-I>S8D> M[XQP];R"\H4]7-UGX/TW$-\]OV!>R9X'\[>0$GL"W_]YX>*2A:UF=FI'5(YP MYZ](TU.4>\F@&*/2N ZY[&BYV@E:JU(,J2T,555U3=4_HN[F8>J\$JDV 30V MU^VF5**0Z: 0*4>=CZK);E),?J8=-)KSURF!R/DHXFRAR#_9-)MN0GU5T%K: M1%OH1?J "FDU?)6TDQZG7U.07J+7Z%WZ+_X)W6S,HSCM(#FH%9%YUCP3>AS4 M(J<-DBT(M=+=#1(SWOPZ2O9U:(L9'ZIUM*18\6XS]6U(?U#JS;/J4 Z;_3FL MW@5_"_'&=\Y'0T^&]D3500[ETQ2:2M/(3P4H?S&5T2S4S!R:2_-HO@C-Q[.9 M^+\4H1F(5818[&^(M8 6@L6TA);2,OQ="/]-,L3/%HGP4EJ.O^5T,ZV@E70+ MW2K_7RXDM^#)"A$N![?1[6B9.VB5\-FN)5E-:^A.M-I=M([67S*T/NP+T ;: MB':^F^ZYJ']3H]"]^'L?;49_V$K;Z'YZ$/WB87HD2OJ D#]$C](.]!E^M@V2 M'<+'3Y^C5^BW] 0]2<^(NBQ"K5DU8M=+J:C#A:B#6U#"U1$YMNIO>;BV;D/9 MN6P!6=)RR%=%O+%,UB/'7(V85BI6.W JMT;5Q+TH@^5O*)$5VB;*WR"-K)5+ M2>WZ>"2B9AX6(?9%2R_FOY^V8P16X7^N5?;M@M_R[1#^2/FCX;@[1?@QVDV_ M0EOL$3[;M22/P[^']F)L[Z/?4#7^-O@C?9;[!.T7+1>D&CI 3]'3:,EGZ"#5 M"OFEGEU(_I24'PA+#M&S]#OTD!?H,&::(_AK2YZ'[$4I/2ID5O@(_1YACF6% M7J%7,4.]3L?I#7J+7D;H3?'_,81.T-OT)WI7:0;?'^D+_%]/)XS/J#D-PQS\ M+.KY$9J.O__#/T9[:DT[S7^9R\U_:2.I5)FHO(%ZW85:V:@HF#?"?Y2K*5;_ M!#/UT^9/VE2X7>O_8I2%=IG?I.:OO7/)38L7+5PP?][<.;-GE-'9,U>M3($9D9Z MTZ-KKVR9<$=^B6=/8)C%.AP%EHE"/#$^FWQU,]@?U9,_(D==PV%, M04&$P!]T0Y39.$[0[1?1W(UCIB)F:53,5"MF:CBF$N\>3(.OZ>'.\+B#?TCW MN&N5_!PO_)O2/3YW\(SPCQ5^/5D$FB&0F(@WW!EMR]+=0<7OS@AF+BL+9/C3 MD5Y-T]CAGN$EL=?TH)K8IO VA2_8U;.P1NDZ1!$>M6O&P!JHTF;\V:"6E%%0 M',S.\6:DNQ(3?4)&PT5:0:8-[IH>AP,;:^.IT)\25^PI+ICJ M#6H%>"F@900"=P6O2 EV\Z0'NZWXK"V*7!+LX4G/"*9XD%C6A/ 'E*"1%.]Q M!WXD9-YSYG1C28&4.)+B?R3V M*^RF0MD:\%$X8'8:O)MX*],M(Y7^Z,@#_=RB"G MY(M+@U?[7<7HGZ5NKRLQF.I# M]?D\WA(?MY(G/MCM(WPN47Q1O(6R1<6V(W/)G4DQ;J_JTGS<6A"X,_&?)VTP M'L2CN4206S1ML-NKN,B.AJ_(&.QKE X"6M+PD?Q(XU>'CW0E^A*M/Y?(DDOF MR4@*QD2D%0]!.$_6=RZ:-2LV9ZB;.Z,D/2*#C1(U9 9E:A?.I\IU(3^,-V*X M.4?:C[0DC%S(5"0C1-R*;=U!RG9[/24>GP=]*#7;RV7CNA;MFY7KR(<+AX,BHQZ/LQQ[.5R!07$-: M$G=E5XTB/,;P#;[@^!2?)UB8XDGD?%[3HR:&XA(G^H=CK&9BNO-D%GC<\>[, M0$&M65$8J$E-#2S,\)<-Q+@(>$85!SRYWL$ND?D)WEM=*_C;+2E+R9J8AJ14 M2JOQ*.MR:E*5=;GYWD/QL-373?0>4!5UN#_-5],9S[R'W$2I0JJRE(4<<'. M4YJ 0(R([SJ$54"%>*H+@0@7U2HD9#&V3*&B6M62Q5L?2A8?2B453W3K2:H= M6X!+/3YXE*!(2#ZT_-<05G!IKI,:D-DF-4YNIJ%(6'8#D M6<1MHM!3<4HSQ56#-"<(<:U24=,DU75(I#1!QJQ 3)95A&7(.4>+2 C?LPJ> MUU""O'SO4W&$],7_B)'&?] +VY:A#T&?9+B+N?_=XBL+^'T\>U ;]%7\4X** M9P@%5<\0Y-@1%XSUE*0%FWK26#Z4Y4,MN8/E3O1\I8V"QN9)-^#W8"+&B/&2 M2['&FL9)NFM-?E=9]*H(A_&I9T@HHP*-D$*360*B)$IWN'QAI>*T-<*/,(+,::."E_0E\(? M]<[RB?$:'Z21GH%!1[*5II','^KE"[3T]!&3#\9Z;-)=[#1!WBC7:TE<".)C M/JN2G''(>9$'CXK\;JN/Y&(L6\HBUF5)2C#GZ\DE@EB7?$A<+"VI:;/88).> M2!#_V-^T)\\Y1I+3Y[,R+T)WR0CX=GRP*7*4'%&5\@74#AZ-XKS@WUW(*D=] MB9/)J:4)GG),G9QID9(3CX/-DD850+M9[S>%Q#/ ?CF&)\&F,HVCEM3))8]# MO6-*J#7W>&Y.C/B#N8.U'_<_:4?A%G$'W/&>@1[^3[P\@O&CD<+# MT?O8X'3461VUN(SHX$ M,_V!S ";J$4%LMKDEX+S4QHEB7&AH/,@(2Y.L"+;[?>Y_3!-E1QO8J(+HQ&N MNQ1VJJ> 54&V59[L?&&J% 2XBQ,L%9\KZ(1B*BTH\21"@P1Y!K)JG_.HRV%# MKD# $PB*<9N)R$@^&<-N%#OXMS#%4U#")G0I6] EXMU,9%?4#J?FRO!@+)= M+.H2%8>IKY#_*PJP@3[-GX*:N"+0,N"^(8 I>!JTAYY<-,D/5<4:R2V:NL"% M$"IA%(=\2,B*V"2)(UI#@',S+Z5FFC.I02+^+4BQ(L>(5)&S"=Y@MAU%C"?V M+$H)JE<.P$,NO#(AWVO/4QH_'H7J346O58QE%9.V#Q>X\=_;LSB:G61+YIUTWO7G$JNLM5%L5 M>2X7A\M\@]'SJ5I/IX(+AW2 T8JN56=JE7=' VW*]P;P+4@&XP'*R'O"+KHFQ%O$SG53>:O]:YX M'VC3!'=HA=*_D#KHTZG:\2[2[GX!G& ,%?TBXRTJM31">8DZJP^@C;Z@N4H1%2CSS/<0GJM,QWPV"7$_%V2(]_".\A/< MWI2F?$H>?D>]DZ[6OJ$>ZFW0<6OI:O5Z2E,G8CY;"K:RUJZ/(:H[I4XZ7X;\ MD38#"%G=#C S2K8=S.+S,>TAL OL%?(2X-A_1-VR#O@30N492R#LJV!NT*]7;C+E'_2&O5:VUXQU[,-HN5"OZZA@98-$7J5 M=9IE+X0>9=ULV0NA [ -)@@[8!MUMO4]ZCC7TN%F&_$.]+;V&]@FEAZ&O@S- M9]?1"M^$/G40W6MDTW0C._2SK1-9%ZKGA([QA'49YE:IMZKTIZG4TELHVVES MHM!''],5MM[1[J+I85U2;ND/;0IE"7T0,7<;J"F>UPTOW<7Z11" K<6D8ISV M07_<#-W7&_%^A3X*U&.8 \;@&3,,\U$Y.=0^M%7M8YX&*T +,:\\C?*5PGT M?5VEL9J&L6//"7.IJ]Z2EN%]']I_JM:.-#V/[I7<"MH8_2G/&$1Y*'=+X]>T MU=A,Q8RZ7K1E+.J)V[J_:M #83JCWYLTGQ'M.9;VB_9<*%F&-NI"6H3M6. H MPS=>IRR#[2N)M >SV=8+VUN?DN8X"]ZU[$:GUF#'Z3];[]ANZ%C MB[[Q->T2=E*"I O:NX*:1]A#/8QRZ. *FJROQ[/U=#_8)FV==R7HB4HP;]#>BMJ8U#I5;& M+)JACX >ZRIUU;6@N] _:\,V!^N9=A3+ND[.S6VUMZF3'H(<;/K)O1WFVU^2B;!'WU5XSZ ML!*K/DPO,MIOZ4XP7?!7]&T_G0$U6C&M@"Z8@7["P[>KM8/.UPWB0KG8E*>J'T E/*@&M3GD"X:8(7Z/> M!!T"M#K8D\ YA+9% MG/6AV]%!YS\^A.L$)=@C(MH7QU#4T"2]54S*NID(^F M()AYL7A(ZU&P')2#97J0YN@WPAZHH]G@1N4H;=#ZT08#.LF ;G+^$T!O. =; MKF,_/'?S) (L!C.!&Y2 .: (3! ,1]ULHG;: M'9@';\)\6$W)6AGR<1!U,(IZH6]D:<_1!.0G&VP"): 0# 0S19YWH/_L0']% MG//RU_6R\]?[0OG#^!BI_ LV1)"RU/TT3/V DM3'T4<^I"G0RWW4CR'_$';* MEY0#-T<]09.5Y\@/O/_)N^IV&J#\2->J$VBP.@K]YX%)W)^-+ZB';E _ MQY]H%MJ^0#T#^Z^.8MC>8#N =::C!'/Q1)JBMZ'1&',/@?O!:X+F]*2SN3+0 M=F/'T4.. 5B[E5)7)0![X"]"[_Z'*">B]FC:@=;@*AGN$(&0A?=;3F&M>,H\ M!;Z0[BF60:>V!CLON>>Q]2+8>Q.O7)A&>Q'A]:7Y.U #:BVPI@S[P[*I$?JE MMW;._$#R/CC.>^B"=@:L;^0"#I% MN*7ZZ8L@]P2,UF$>DNY2=BT[TOR.W6;UUKLA@[*?"3PM[@>N SV-Z/1%4K0%64$IZ;N MX[BHBS(9YU=$+[W^&=^W]8JQ']:%R7YC7GKSGFR;W<;$6XG2A^\MB?D/5,:VIVL%K MG1%(\R!(P+C%?(_UT4 Q9U]H_SAB7S^\W]Z5;K+G>:0?$[/-2IN?.7D-_6=K M_8PU^#>6/C$_1CGG8YW-:[$Q>&^06&MYS1=1COGX3B_^%N=7[.-C3D&>QV+] M/3Y@WW>(.G*+LK5'RRRSQ+ 3GF> MT _X02FO-VW..TN(*I]]3A!Q1K \ZHQ@Q+]S/L#G )%G ;R \!O$BMP_O^ M7)='S(>Q3G+Q]T1;+,)W/T%;I$.G[8<]]%O(9E,7N?^G:T_)O=S>O#=K?NT8 M;NT-\MZ!.HRZ:$]C#AF#]=80\@DYUFF8T\6^'^PEE]@SX[Y:"CNXC+*=7%^' M83MU1-R3- EKPLE"-_>E%6!=)-#KA8CC9<3^\QCS$['G^A@-M/4\TNZ)-:5? MI&OMQ2)=\T7+9D!\81N$WL1W2F 'G.%WU-?-F]37*5[OBSF@+]TE^F9?V-Y_ M0#G9EAZ#/$N;(WJ_E&T =3T]J']E[7$ZMI#?L1G?+H1>YS4JEQ=]%>\.5E/- M?S)B']5$77T".V*Q6.LLYKC*#UC?=ZEM>]%]I;CMHS MS[;WS>WR2V:"5FS7H.P=)?D1^\ESH+_7RSUHQL=K:YO(? BL.FC8-Y;/Y?YP M ,2B7LV&_6&!)OK#$W(?^ GS;4;NS>:!E7*O=JVVG93(O5FQ'VOOR7;#,VL/ MEC@NTGA%Q.%GJ#/E.\H5??$D=<.S^_4BE.\#D(YWCE!_U.,@]6L:K+5#/QV$ M[RZB&-ZC 0G:<1HIUI=\9O4G(<^%/;98WTVE6H#*M&S8CZMH+M:=K=0^L%E. MFR'>QW/TH?OT^_ ,=IFQF>9C3,7(LYYW&F$^TZFQ[#.L$ZTSF'MAWVZA M.=J#E.=\DZIB\C .\ZD*:YAJQUM4Y2S#>(2]B.^,$#;?)KK_O+.?B#,Y^ZP, M>9I@VX[X!MEI\S-''FRW0MHI]AS_8;YLV:.PN2MHK'(Z= +?6HCWKA+OGC%W MHQS%^ Z);R&_X@QNB]ASFJQM1!FD/1M]'B;L3'YVG#IC#NBB^0#(8! J/#9XKV7FPY/03<[$=YN_,^FWT^"&Z39X0$NH+.O.=F$W%& M:!%=;GGV%W'N-P3+MN=7 M22+/U.QSM,LXS[F<,QR,W?L;SLW$GM\@[>&&^4_H F"XL%:WSARS]'Y@$.:^ M8=8<*\C!L^UTM78"-L1U8EUGS5.8'S#'_2#VP&=B+OJ[N4?]F65XOA9S7A%M M%8BYSSPBWLNU]B,-Z$"QK]V?\C#/>2*PYK^[D>;=L&4>I#L%/+=_:9Y4T\Q_ M"3=@'L7\-XSG0,PK7?1ET %Y=*\]WXEY+ =YYCGN3^ YS!^_HTE"CVREZ<)% MF0TGS> ]6)0Y'[90/N^9D/M8\J;V#.:6%^2ET;:'>$FD>I]FP"RIU'VR) MH8B_@/)XC:WR>N8^K(^^I=YB[Y;K:0GJ_3AL&]Z?WHLYL2LE.-Y & MI/$6]"LS%#;(;(S)$LHR7J4L1S'6-7\EMZ,YZF,\I6F]8(^P#D$[JM_C/3S3 ML^$B#:,7K88.57B-"3N<>)VIGD-^[77F7NC$7UYG6FO- S22UYMBK2G7F6*- MR6=[U=89G9XBS_GD&9]@.=:ES /4G<_Y^(ROT?G>..HO7'G6%S[?^P V_23K MG$\=3;>03M/TCC.10V@F,=^C_&@SH+ M?;$,? ".2ILO![8*; G8J7X=-IKR+B[!/Y!CE, 6$YI?'8*G.'S MT\U88^X3YZCSA/]O8"O"*Z'O.T/G3K+J7'.A/W: B_)Q?6O]4>=\ICK/?$_Y M3-0[H!PLAJW&[?2%5>?B/=0_2%(UL %I\YGL6KI:.4H3 MM;XTL='^/M;J8KU>225@KKVGJ&=1.J/FT/?BO);/<>'G_0#A9]D-&$ZXC5X >IFNG56+,Z&^3OQ='\T^N3&0#8<[L7H%0WBLYL4#>3MX9X' MY&EP+T1T/BX6+^T2^;B0/!GN>?RG^;A$NAZXYW&)_&7!O1"7FX^+U7-GN.=Q MB7R,@WLA&N4#?:N0$;8U[POQF=0^S/$68M^'][BXOX;WU!!/G'7)/3(;/=7\ MB=%4>E#L>3&=Q1X1.5O2GQDQK_+\R>.-^S'?F7C?-"TPO@&?'4="5%?*--Y; ML](67$S^CRAL>1=K;TOL_;TOPQ'O1^^'1J<#&^(91JSEK7N/PVT7:^[F^J30 M,7;%G@+'F48=#=BT^BYJ(>+QVI_/[*%_0!J?S>OO4HYC#=;2?-[>$NLF:_X< M9+OBC+T<YGO]U +/I=G&T-?!OC\"/I7WL<;&7;7H_^L#RT0;K:X MHS8%:]&.!L$_#;;S!XC'=]>JS)?UJE %,+?";P"_X:(< 7P-CYSN/0[CA+R M.$K,EQTEH0 HA!\R\Q7X-]AA[53H6_WYT"JP0OA?"JV5_MU@FUX7^M;X8V@5 M6&'X0OLN$-X-MLF['Y>,ZSB,==;AT+?.;:%58(7S*I8U#JMZZ%OU_= JL$(M MN&!X-]BFZN8XL,(88SJ,'T.K''&AE<+_?>AVAQ%:8HP)O06J]4ZA;[7/0UN- M*Y&/5J';]!VA?0B/L+#.0XQL\=Y*1[-0N5$9VA<.7Q&ZQ0HCK>Q0M74'Y=)Q MG0DTW9E@.IS/A%8Z_Q@J=TYCF0R?#-W"X?#]D5\F_]^(V^@]^RX*&"_="1(A ME_=3-H-[P-:(\.:(,..+\%]6?(Q/1>UCK@6K02'"),.,'\2K?4)O2?\W8"7H M!F:!L@O)!1<3=F6%@$=^AL>_+_"_X=^[W_EMW M@0_],O*\:Y0DVK\R8EW^2RRXG'B.P;^,=<9F%DI*S@^;\!^ U^(\U_[77/-';3V(DH?O@OV7<"S]92YGSK^<>?ARYK'+ MT1W1\SG\8Z/#Y\V'":&"1O,APK;]8=L<\VBGR M\9D4(^_4M6YTKR[RG**0QH3OQS&+:1'?N>1[<*(\=UKG#"AC/\R_:#JSE#UMWQ5"?XDZ8 M]A6>CT"=+<(\_AZ>?P=W ?0%VT'M*%:L.9D#U TV4*SV)6SFPX)*_1BU8\3] ML[<03J0VO$>B3Y3WPIZA&5Q7VDGJ:9\I8'TZ*;RW9-U;B^']%SV7MH$'PO?1 M@+:!]$9W@P]3-[X+QW?,1'EJK#UK7@,[\LAO/(QR/4M9CJNIC2,;^2^P@W7_#W1!/J[4'\0S!?/8+T8\51SOD81W6[^DH0P65Z5.1+UCZ,63=#V97?1+P[Y3R(,N&^QRH MI(@?-9G_#W37FV,M!# ^[^5S;UZ3:UY:9Z_5]=U@F1*+9^?4F[ F_YK&V[]7 M@HW>A>^8\;Z?T9W<3C_Z]TAQY]-M_"C.^EP\#F/V4A]]H!G25U&B?H"FZ-O( MC7?=G ;?/P-<7Y\;V^ESOE_D5.@YN(7Z!.5=?0*]H!/61J0\;V'[S9_X_!=E MG\+C&6DMTD_00*.0EFBO43SRM%7O13/TMABC^92K-\58&T8+M&2T%]^/E6!M M=EAR3+#/W,CH'Y'/^0^*=7Y""2QUBIHJQ/XCC,EP^8S9U,OJ*^Y4NXTFX%>1R-,68&D=M^,ZO]K9YU)F! M/OT(Y3O2,+\@/O=Q1RW-,WZ/=LZEEACG5?AN)LK$^K^3N,O%>O2#] NFZPV#N7P;]5XS:F\BO;G_;8:,RMV)SVMGZ3-ZDE: MS@<0428]VO">N!Y<=]AHY&M_(WOJ-MQ M.0[^0"/0Q^ ,_[2U47J7(/I/.#^95IIB[=U"WL_/E,]&2G99B#S.$/$?!7R+ MOY/T-^(B:Y'F@DA;K[:!2)LLPJY: /ODF 7B7,2>0#UC]-:W!\O!>*)S(7 6 M[4 7=R]%_0FXO2W.F>=39_\N8;]T0;U+TC<*O^0F"7I;_8PH;K>HJX*[P+I[ M4_<-^%[^3H)Y0GZO5(9[23@\0^;Y.[CSX/X =Y&D1OX&XSM)+ZL,7%?6WH=\ M'@EZ0/W-R5E$EDOX?JPF0B2)=TD7:+H MUYC(]$4]9$I&2-3&B+HME;^?B:1*8LZC.ZZQRSJ_]B8NMD,[S%@G7#<@MKS^?YY]P?DN=[ES)'_2_1;Z3', M[QXP$;A 3V,R[-SFU-$YF9+51=29SR'X=P?ZI\+>; $;N!!V#]_M-+4=YL?B M-QZP:PWH,&,735-?IWYB?ZR"%HO?7?'Y$-^A>9$&02^6*WQW7[K"/H9.,S; M]IY'B>*.RCUX]R7HKE+DHXPZZ5? ILFV?K\9,PKVX U*<)13DOB-,=K3&0=] MO5N*,D<\4]\"N[00;$>G9+O)4K;F1CTP: M+/@095Y(";!/IS)J(0TV9I%?@#7*)O-C>?>ETM#1 M/D,IF^_/B7.ICF)ME&\,@'L]7#L<9];B>S&HWQB4*<;H#ENM+\KH15]ZG>+0 M#P:*WREN$NN1+&,P\HLU/N+W%O>J>L(NGP([,\2< MY#M6YO=BS; ;.N^<^3W6&JU%'^7[/8]3 MKQ*G V\OX,;)E1#,;=$OYMI0VW MK6A?A8KYG%[=A+C_![:@[I$6UC=#C94T5.SM\MWDW=0E?#=GH7F6?V^EO0#@ MPN;'NL,37#TH 'A/M61;N0^8_=99R+B?T!M>&WJB$.;7(VVXO7,'V&S#D:X MI7E:'V$>:3*?C!@-:Y6'R=";T96P]S0\;X.V[PH[#GK A,XQ,:+->-AT=>AW MM\ /76=>"W+!00 =98X%F#-#O\?\]K*T]<=:T$G(CP/H,+,/R)1I8)5@3K?B MA#B=4OE.'_E\AA6'_X18?CU=UA^1IX,7D?^>?X/#^<>< AV@K\&#R;!3[X=L MKZ0=OC=?_8K$+S#U+)JMSZ'9V@^4HOY [3#GM-7OH8U8UV_\_^R;!WQ45?[V MSYF>.C/II,U 2"@#(85 0I ,O23T#+T%$B 22$@!01%$4797=$5<=<6ZL):H M"X-(%NM:L8"*6+#CZJYE6;&O(,S[G/N[/P@87 3?]_W_/Y\;^,[SG'//.?>4 M>\X]]V8BW\+<&H_PS>C;16*!9:E8H.+P_)5DOAWLP7/K!;BFU>_OMX'-6#OO M$^5:OL^%S_([T1G/J?%X)I]J*0+E8J&E$OOIY7A6^1#/QJ4XSU@\&Z$\ZY5X M'KM&C+"\(7I9/L8SVG:<1X?_-DF5B_K;5)PJU[I45%L>0MZ'4,YAD8UK,M6* M-):'19+-C#)^%$.T]K5J([>3VZJU%VU5;38-$.GJ'%K];\2:B_:J.*V]K=NL MMQMKP/D*U>;C[57M1!M56[4VCNUMJ*=JKUX'DW%/X,Y?@AAS&G2&N.2HC3KU_4M\ET?Z>L[/^/5[ZKNQ4 M[7N[_!U8^IZR>C;/T=+2LWRA]AW7^[3OT4X^_G>^T^E[M?KW;$>J[PYKWY?] M4?N^[P;DOYN_,ZN]9YN"=5]_7Z;_G4R-6O];?X=:W=-0G^G\MW7FZPALXC1P M+5::K\(W;9 MOA&[S*^*V::YF#O]Q&![I=$D9H;NLKCD*C#1XA([ MP5#P)-@.K@-E.O=8&\0N4X88;AHH%IO]8@+N<4^'+Q276?=@_S53K-7+"2!M MBT5]5\ E:L$2<&WK5&H^=AI?Q#*]PB@M-$F%% M$NJ0+FY1F%:'[F(LCXIY8"_*GT]QHKOZ&W+H5%"CQ_&QA;J>KVNS5H9+K #/ MXGY7B[;6FH>*.HM-E&/_5FN>)::;KQ)%YL]T*D713]+M%W6X_T['_;>P=3KS M#8CK(OJ:ZE"_.O$@& [2P0C0'W0#*3I%(!8D@@S@!8-!#.@-,D&6GK\S:*?G MB]/\7/$>>!)4@TQ0 ^:#2<"G4PGZ@@%@(A@&FD _, .,ULD&8\$@,!3XE;<\ M)7+Y#J8\A=5]ZMBWX ?PD>[3$:_^IN0R_?ZL[JTC=.V ^,^AB>K]&Q@.,@&> MQT)X?@K% '5_5FO-/;H. NU! =U[0]?J^53^>/U^7P3PS!DRTWTS5*R?"\]) MH0O!;_2RSM?C<)YC#^EE5.BH^E;KZ;I0?DW3]?.H_4=0WV?T.=D?^QB\11J: MK>?IJK?MAE/HCG1[H4/U?JA5>QIH!,C0SZG:VU$_;U>]+GWU=*I^L 6_)-:'#IDPM_"QX0;X7>EB^*RS8:TP'*^6[H0_ ?O@\ M/?PX>,I6+1WH;M^(=?]MS2FL;^8F_];&MN'J.^OC.7Y7XFGL4[]"EC3 M?ATL.U&G7P&LH9/.FB_QG'RV3!+BG%BHZ]WGR&VD=I\H.U.L=HS!F3+WS+%? M@_+/$,>0MK$E8!ZU19^V<50A7QO84D5Q:RROX9IKS3&O0?&YPRP_/!3SO2\5ANNP5.9 M((K;PN[%^MB*\#XM8&]U]GAV(^^VHSQVQ>Z*RP,U^], MC$EU*V:>0.[&/7!_*W:?P!1Y>O#L6W8Z\$PW^21ZH)VM67\REC@\Z[1F*LKY M+YS)O?],[N5X#BO[;U@[XOH#YEO(6YS(YZ9S*#7W(TSOZ/X"I,M&>EU-SV ^ MG((ZIG&+CO++L7Z?"XDHXP7H.6!Z#G6>>IQBD*M3=@I%;<0=YRSV:;]L_)K/ M<'ROQQB>8(A.V2_!.C54;"D-"?L[F%_ C#4*SY3Q'/Y)?7%,899BI8:: V^* ME99\L=(Z&^4]#'"?MF&'?CJU'(9OAO9'&UK[>:@3T/;9V*-;^H3V@Z.62;@N M%?N$&11;OB(WFO_?XARML(XZ&2VN6:\[GNTL@PA>S\T- MN.;.A=MTO>(<.7DOV/^DL+Y'.X-[[CI0>]+][C3W$ZRM/=0ZB&OF-ZJ/S ]H M:T?GMC!W1YXV, W&\=8,)$Z90_D@0WYW[!4]/$VG Y@. FVD5\UD7Z][M>WXMI6OG6Z-CEE'=@$-H#^>GBSCDJW M$=S41GHN8WTKKFWE6Z=K$WD$]?SE7'>6^?ZO8P/Y^SN_T]_W#3WG?GP92 M]?/M1+[W]7?[^_5W^W'ZL:ZG>;>/M*'1P-/JW;[RG?3SM]>U7:MR^-V^ZH+!>;V&)/^(EW]CMO462PVE8GS%:JNZO> T*OT,J_0V]-=[Y<) M^N\1U._C!X#K00E8K[=%^7[Z6&2#>_7O/V LCWVC]^$PO4\*]/)ZZQJF@V/' MEA#:=R74MTB=1$CU_?U@*:@!D\$B($ZILU[?8W]K5=^"5G75ZWGL';V>JMR) MX#:]KT?I^5K7=4K;=57ICAV!UNOU8E2]&K7KO0^H /U.;#OA%I["XO#+H0# MO116"*;C>0G/9 YWZ!U'7>CML &A=\+FA]ZV#<,SXT#P/=:XR5CW7A=ECGRP M0Y2%]0=X;@][">&OH"X<+T:Z2Y&^G[Z^]H9? QU*6"<2MD@0 1*1!\_M]@O! M+> P>4>L'KX*Y7X$WD#:W^+9#]C3X3=!1X"U^OO6$?3.S787J7I.M'> CD?< M6L*RF3@>MA(JO37YQ'L[Z[>D83D@67_/OQMY2A$?CG-EPB\''1%_ .E3J5SK M%.B>$^3QR:730Z;'FRRV71GTXV-CTU7-EW8=&;3B4T6FTPV'=EDL.G ICT; M+QL/FW0V:6Q2V:2P26;3CDT2FT0V"6SBV<2QB643P\;-QL7&R2::312;2#81 M;,+9A+%QL+&SL;&QLK&P,;,QL9%LA&YDB,TQ-D?9_,CF")O#;'Y@\Q\VW[/Y MCLVW;+YA\S6;K]A\R>80FR_8_)O-03;_8O,YF\_8?,KF$S;_9/,/-A^S^8C- MW]E\R.8 FP_8O,_F/3;OLGF'S=MLWF*SG\V;;-Y@\SJ;U]CL8_,JF[UL7F'S M,IN7V.QALYO-BVQ>8/,\F^?8[&+S+)MGV#S-YBDV3[)Y@LW?V#S.YC$VC[)Y MA,W#;!YBLY/-7]FTL-G!YD$VV]D\P&8;FR";K6RVL/D+F_O9W,?F7C;-;.YA M;N]C;/;#:SV<3F3VSN8',[F]O8W,KF%C8WL]G(YB8V?V1S(YL;V%S/ MY@]LKF.S@8J-NO87,GF=VQ^R^8W;-:RN8+-Y6S6L.%M MC^1MC^1MC^1MC^1MC^1MC^1MC^1MC^1MC^1MC^1MC^1MC^1MC^1MC^1MC^1M MC^1MC^1MCZQGP_L?R?L?R?L?R?L?R?L?R?L?R?L?R?L?R?L?R?L?R?L?R?L? MR?L?R?L?R?L?R?L?R?L?R?L?R?L?R?L?R?L?R?L?R?L?R?L?R?L?R?L?R?L? MR?L?R?L?R?L?R?L?R?L?R=L>R=L>R=L>R;L=R;L=R;L=R;L=R;L=R;L=R;L= MR;L=R;L=.7";,BVFRX+I_3S8,P?3XR&K*71),+T/9!6%5I)<'$R/A*R@T$4D M%Y(L)UD63.L/N2"8-A"RE&0)21,=:Z10 TD]12X.I@V U)'4DBRB) M):D@6 M!%,'0\XGJ2:93S*/9&XP=1"DBD*5)'-(9I-4D,PBF4DR@_)-I] TDJDD4T@F MDTPBF4@R@21 4DXRGF0M/^?PD)92O'\EY)'TI93%)'\I>1%)(TIND%TD! M%=:3))]*R2/))!6E'DA1,'@U))$F@R'B2.(J,)8DA<=,Q%XF3 M(J-)HD@BZ5@$23A)&!USD-A);,%V8R#68+NQ$ N)F2)-%)(D0A,9(CFF)9%' M*?0CR1&2PW3L!PK]A^1[DN](O@TFE4.^"2:-AWQ-H:](OB0Y1,>^H-"_20Z2 M_(N.?4[R&45^2O()R3])_D%)/J;01Q3Z.X4^)#E \@$=>Y_D/8I\E^0=DK=) MWJ(D^RGT)LD;P<2)D->#B1,@KY'LH\A72?:2O$+R,B5YB60/1>XF>9'D!9+G M*)GF*Y$E*^02%_D;R.,EC=.Q1DD1^DOM([B5I)KDGF(#U6MY-I=Q% M2 MZT@VT+%KJ93U)-?0L=^37$UR%\H]%N2WY"L);F"Y/)@? 5D33!^ M-N0RDDN#\7,AJTDN"<8'(*N"\5B,YRBD=] ]"=(KZ)X"*:!C/4GR@^YND#Q*F1MTJX;E M!-UJ;O8@R:;LW>D,W4A\5%A7DBY46&>23B19))E!M^JECB095&8'*K,]%>:E M4CPDZ90OC225)(4DF:1=T#4=DA1TS8 D!ETS(0DD\21Q)+$D,93!31E<%.DD MB2:)(HFDE!&4,IPBPT@<)'82&Z6T4DH+19I)3"221/A#SMD>Q3'G',]19Z7G M1_@CX##X 7'_0=SWX#OP+?@&\5^#KW#L2X0/@2_ O\%!Q/\+?(YCGR'\*?@$ M_!/\(WJ>Y^/H^9Z/P-_!A^ XCZ O@_> ^\B_ [T;? 6V _>C%K@>2,JU_,Z M]+6H&L^^J"S/JV O_"M1/L_+X"6P!\=W(^[%J(6>%^"?AW\.?E?4^9YGHZH] MST3-]SP=-<_S%/(^B?*> '\#_M#C^'P,/ H>B5SL>3BRWO-09(-G9V2CYZ^@ M!>Q _(-@.XX]@&/;$!<$6\$6\)>(99[[(Y9[[HNXR'-OQ I/<\3%GGO W> N M<"?X,]@"]=26>A9 M'5@5N*1Y56!E8$7@XN85@8@5,F)%RHK2%1>N:%[Q]@I_C"W\HL#RP(7-RP/+ M DL#%S0O#>PT72[FFM;X^P:6-#<%+$UQ38U-YF^:9'.3'-0DYABP. MU ;JFFL#B^8N#)R/"E87S@O,;YX7F%M8&:AJK@S,*9P=J"B<%9A9.#TPHWEZ M8%KAE,#4YBF!R863 A.1?D)A>2#07!X87S@V,*YY;&!TX:C *,2/+"P-E#67 M!D84#@L,;QX6&%HX)# 8C1>IKE1OJMFE*C J%341*7) 3HH_Y8.40RD6D;(E MY?$4.;B=KVZUL=W4[LS/II223/ZE+MR'.Q)<2WT_\(M$2 MZT_LDCU$)+@2O GF>-6VA)'E0S0M&42:6Z"UU9.0D37$&2^=\9YXT^ OXN7E MPBR]4@KI@I@=2/. C/<,,3^"*"&L0LK?BW)?:8M#C"O=XA@S=8M(,EDWXR&I@;?)/]YPOV!^Y#;'/^8ZR67R>F43F?(:?([ M47EGM"?:I#Y"T69_=&[O(@#BD AZ UZ@0+0$^2# M/) +>($'I(,TD I20#)H!Y) M(D@ \2 .Q((8X 8NX 31( I$@@@0#L* ]B!#5B!I7\(GV9@ A((42D1)X^! MH^!'< 0!^^!=\$[X&WP%M@/W@1O@-?!:V ?>!7L!:^ E\%+8 _8 M#5X$+X#GP7-@%W@6/ .>!D^!)\$3X&_@!0\ AX&#X&=X*^@!>P #X+M MX &P#03!5K %_ 7<#^X#]X)F< ^X&]P%[@1_!IO!)O G< >X'=P&;@6W@)O! M1G 3^".X$=P K@=_ ->!#>!:L!Y< WX/K@97@77@2O [\%OP&[ 67 $N!VM$ M9?]5$O-?8OY+S'^)^2\Q_R7FO\3\EYC_$O-?8OY+S'^)^2\Q_R7FO\3\EYC_ M$O-?8O[+>H U0&(-D%@#)-8 B35 8@V06 ,DU@")-4!B#9!8 R36 (DU0&(- MD%@#)-8 B35 8@V06 ,DU@")-4!B#9!8 R36 (DU0&(-D%@#)-8 B35 8@V0 M6 ,DU@")^2\Q_R7FO\3:\U6IB%712)D6*4N'[+&M^DAT44KO0$ MT4=NWQX_:)"CN_U17,4FX<4\<&"+/-#OM)BB=B0GEV3L*+"M,[N'X\'_@1+[ M.JSP)4??.[JGQ]'W#L84]3@H>[Q[X+T#KB_WN(MZY!_8=R 7._ZXY*@=-H_/ZPFA*_R;ZN!H4DE?B2]_CV]/#M\:$87T[N9.EN[]:( MBS;9[7&VC [9IH).6;WR\_/ZF0IZ9F5TB#9I<3U[]>YGSL]+-YGC.*:?286E M>>^/4\RCC]I,%V>43,BWIB<[XZ)L5E-J4DSWOIFN\5,S^V:GV="THY?'IZHR4N/CJ:RC M(_&X<;\0YENMB2);1JI>]W?LF"X[ILF.J3(C179,EAW;R:PDF94HN\3(+FX9 MXW7)D3EJUQ_E-(VHSPMT2^D!E@>[;AC+=ZC'!I84Y_G%5!/20/PPY;L,8Q,:TR))M M&>.ZN%JD?:NM7)0QZY]FZ[S9:5I7SO3!K9>+[ MDF-CDMUAYC>O"[=$I2>ZDUR1ML?,%HNTV"-L1ZX.DE?NNR2)K/2I5]U?J+J?+],2$)');@BHV19@NK,A!93]P?S,_%/%.DC M4K03>]P(ZL((=*D_PJDZO;#(ZRU*:9'9#^8GV++'NXI:9&?NQYBBHH.8*Q#9 MP^<[X-M=5-2CA^L ^E+KR>FJ)U-V4!'9J@S,&BK%IHHYT94HP4<%G=JCO6/[ MF0MZ9IM.S)A^-JU7M9G57O7L1FN8,^QH072\TVX.=T8>F5A=%)-:,*;G>17# MI(*IZ\H'C&NNG9"4,OK]UMRGCM7]79NBZG 'SYJ?-:H44FQ M?'A1VR6WQR=HG*FJ)PI6LX4E3-%GPXI&*_MPJ%F$#(_@'.) M:/VRC]9G4K0:[E@,7G2Q'\%BORJD1['4IH4^/?SA*K+87>Q.Z-4B(_SAP\=W M^]KKM0X?GX#@5NL$#&N)6@J+7!A8#*;/AWFB!M>W3PVP^HE)1+R*<<<4:6.M M#7:*/])9+"/,6MG#M<*C:L9[NWU=HQ5O5>4':W "C+!?T73^KC=-C,T5%A!>-K!PVH M'-3!-W[9R LQVG9;1'38X@'5PSLE]QQ;T*>B+"\LG=K= MVV]*\<#:,=UE_>2KY_:.3_-$1\>EQ7=,]69Z._0+Y/6>Y.^ 61D?V\YI[^"? MW+OS\%Z>C,X95F=*@C/1'1V+*R6[O&GH>=5CBR),]H(Q"W +R@D=-K]JC1-= ML6IF:C.T3V:VS.HN.W63'3O)CEDR,U5FI<@,;?G,3)*9B3(K06;%RZPXF>62 MN$@Z6F5'B_2E2&TMC:&UM'M"$DR"6F(3],M Z0Z,?D)J=K:K)?2C/PTI7&K: MN]0UY7)AD76%1RJ'J\CU$!Z..@D+K:26EM#+:MI;U+0/QV&+):='IY1L[1*Q M^-J[7.'MQX4'1(D:N9BB_(-Y>>X86:0N@GRZ*'QY[OS=FIZ8^:?\I&SKE.+2 MBHRH:55F$A?JR\O3K@1;1H:;;X;NX\N /+&8)L@,V=[\:ES,>D>USTUWKW?'';C<=FRKOE'7MLXX=:K=&^!WZA[&_P] MNK>+8G.+*L42AIA4\]>Z-XEHBU/W9I%J2=.]!;Y(]S;X +R$%Z+2LECWJ(_E M-7&W\(H\D2-R16^XD:):S!'UHE8T@+FB$7$#X>I%G?99@9AJN$4B&T?ZBQK\ M\XIQB)LGYN-8@Q:J@E8A]1)\5B)EE!@&-QLQ56(I4HQ&:54HHUPLTYQ7E*'D M92BW23MC#=P\K29>4(LTRY"7S^$]7N<=@1"\Q&KCC:A?@W'VU..^&JM#36GK<]C0JN5&O]*[9RJU@NT]LT]J;X_O7KF:>$FG)M3J]%8B+ :F6JM M=MEW>_-RHYW3FW=LGJ5 MPZM*SLGW9BGIWID655?7>QOE5 MWI'#R[UEU7.J%C54%7L;JJJ\50MG5U565E5Z:RC66UG5,*>^NDXU3SM'955C M175-0W;9Z%&#RH;Y!E;45,^NK_ZYD"ZJ-A7>QOJ*RJJ%%?4+O+5SJ0;'.W)> M?6U3G8J>4[NPKF)1=55#-BZGT6*4& 0=)GRG#+B:O/,P7#7:$/]N^+-3.= M?;\5[1S:\O[0YQ>]J'3?SNB_'SE\=%78OQR]$%3KN[;^_Q\!!@ S0Q#L#0IE M;F1S=')E86T-96YD;V)J#3,X(# @;V)J#3P\+T)I='-097)#;VUP;VYE;G0@ M."]#;VQO7!E+TEM86=E+U1Y<&4O6$]B:F5C="]7 M:61T:" U,3,^/G-T^Q_^(C( G1D_>^)+QF3GOF.4X M;R;F*"K@@B(:28@Z1HV*QB5&15 3'9=QP[C@@B@"0M@17%@$!0549(LL(H@B MX()(KT!WT^O[-==I;U M@:* [;U'TU7W6["C$ 1!AA[6)(">ALV3K/JMOZA&I]%BIR$(@@P-;)4 FA9( MPZ+43YYCUR$(@K@[=DO F^0MFK&EO[@&.Q!!$,1]<50"WB3A^!!%_CWL1@1! M$'?$20F@DFCB>F5U,W8F@B"(>\&(!%!+0Y+E!S4",78I@B"(N\"1A $X2TL2L! DH9'8R$UUE03H=X=_/H$/ M"$$0A'E4&K#MPC%+#/96D5=.9)%=N ;772@!^KN?RL9GA2 (PB#RU!O"_UI@ M9&P] D 4B&RBF>$NEP"!UY3^DEI\9 B"(,ZC:FH7>6\PM;22E8>)G%JA%,RO MZR5 +T^!FDX!/CL$01!GZ#V4+/"::M;,]M^H)C+WGHJQHZFUK1PT'81=,E%/ELLN)FF\;>B/PV\T<"<%, &7HDYS[T\(L: MY7T(TOA%R2UM* 0(*ZCJGU@WW9(U1XDB(!F"X=Z\D@"!YW1U>R<^361H<*_V M!67\#6GL_ 2E6HL]@S!+?U&-P'.F=>MJNM_:=SK[K?O-$PD8/DDT>RL^4&1H ML'9?$2$!D(HK.[!G$ ;1VW\OW\$V6^?J-*3O0=\RYH\$Z"-7\^_A8T6& (NW MYYE*0$9A,_8,PA2*@@J!E\_@QZ\VGB0*:IYW&5:!^"8!PC'?FPH6@K@=IU+O MFTC X8Y.*?8,P@BJNL>#KO]025G^@"C;&YEIM _+)PD@VH,@;HJ\7^,3-32^=_S:01WYK6(!P?PG\) MT(M712..)01!W(O:IJXQ7R>\[.K9$UV^(#QWY:["O-)6D53QQ<*4XLH.Y]<# MB67\05:!PDQ6@9X\M[[]RA\)D"P_B,,)01#W8O'V_$M%+?!AYIKL;9%EA^,J M1_A$PK^E-<_\UV9#S/.0G*\:I5&.#+8CN7TT8M,ZQ".6^XV$C!\ MDCSS)HXH!$'<"*]9,2JU_F032$#PEIQ/@A*CTNY37WGZQT!RN.:^\SEVV4_I M]G-$#:KFCD'C\'DE >(%>W!$(0CB1LS;>*6HHETW( %1:;5I^4T?S8W7:'7U MCUY/6)H.R>&:A6.7V+<*U/B4J*%G=[Q[28# (X#/)X4%8OF-\O:8BW4'8LIW MG+R])[K\MPM5R;D/R^M>2'O[.6O&G?O/RVK>IF>O>KBY+[@Z.25/,J\_@I\< MG5$+H]V0X%^X")W3\9*+P[#R?@W\\.+*#F@/I(S"9K@[E1*N/DC*:4S-:RJ\ MV];0\AIRP]6[[ZWS<6ANW%ZYJ[B.+L&0/3IEI/7=V]EJJZ?K?M'XM397+ET80J MT *H^<=]-QZU":?_F UR ,FQ%O87U]@75#EFB1D1&;/$S22 EW%!\"(?^[UZ MPI)4^L%/T_3QO'AX[FPWIJ;Q%7'?15OS..L'ZSU I=&!<6%'2UK:1>RUI/VE MQ):6#*2(KY:E[3ISE]DX;4N$'R^CWQU,!]MW!"-Y\<:C::NSK'3"^SXG5N^] MWM0J8+LQX L1MQX[/\'&LCTRY0B?2*+XT^<2'@PA?0+OPDIM!V(KP#Z 3T)I M5D7=2Y^0B_ 6.--"\<*]=EE.M[:IRY:R,(4Q+5MP^ZE;2 ]G_^IJL?SHD;%1#K MO^X23$Z=:9Y6H1)XSK1O%:BIG:A$NOV<.TJ :/96GMC_;I$\N$L L\LME]JT"C5MN6HEP]")WE "! MQUP^V'^!6#Y^4;+I2/A@RC&8XH7L+H29=PL -5_X:E$A]]4E0(MNMRBUY M8G9\3ER>SD&?$!(P+CCI6&(UM1<0$5^YAESEY@DDQV^_OZ,"X=?N+P/SN M.'G[0$PYV)SU!XI!OM_W.6&VNWZ.8"OPC#,).)%<8W;!9V%XWLY3=^!Q0%?, MVWCE@ZG'3+/! &9I+A U! R?I.F6Z%R*1JN;]=-E8C1^-#<>YKDRN9D- M/JE,>;.B(S&']5V,Q=OS+7DI=NV[,2(!"\)SR5&GU1U-J!KE'4'/]OVOU]A^ M?TU;0J%0:O)*6_W,K9.#;+FO!.28> +O33\;FU4/OY<L?/ON\X?.(V=8&)X@:O6UCODZ@UR.2 M*MXU"5"6/[#+8/9&I) U5#4-8F/Y+0&F9]RX)"JMECXV1OA$=G1*=3S )^0B M$6LW86DZO:G4^1272P! Q%#98J,X>'_!Z!EMWT\^POAI#K8EX+5 1GC:U^^V MV5AV_8%B8F#WR=4,MBVOM-50N:=_S**M>?3;E==97$N'.1K=DPG94T@O6%G/ M_%Z2"R6@_U9MSYX+TBU1?:>SU1WF8Z7ZSEZU;Q6HG5QGDVX\R4L)\!;Y;9;N M.-^S*UX\[U>!EZ^EG)(?#KK0TA)VUW'YOPIX(@'& M9BJ"\0,^CKV_(.6$)YQ6T.Q>$D#L OO9LU3>^DQ$S(.<#%PDB$QZV[:_+TXE MFAIZQ.)[1-^L6;;CVI[H/:3"_WH!O/6O' M*M#?5IO6(!@VGV\2(!RS1%5O--XT+[I%,[:8S2R>L\U5EA;\5>(UJ6ONTO& M S'EIK'6;2_$A%_'ZH:%C1( ;AL]VY=+T_CS_@88KSDS'AK$M@3XKLIT)E)Q MXG(C]V;'*28WA=?N*S+4'+CA2D/+:V)5WZPG\.Q5#V'PXR\WL-=(ETB 5M0# MR=+BO#0\FGS1EA^T8Q4H,I,H;LLZ$M<2,"Q(\]K8.9HP,3UKK*T MEXM;C,;MK!@^V'^ OD#ZV8)DPW7B6&C"U0>NE0"E6DN8J6.)U?QY?_?'5!#A MD6XD ?)^#7$0H%O89U<-VR*-FC=_TU4&FT=WYD$.X,I'<^/IMRNIZC M14P6 MND7R@6V+MU>"PU@QSEQ*@'1+%"3+%G*RNL6H9Z0_GQ!^LLS&I'E.^JB2-4<9 MEP#;VV,VR;-*+74._';!<&_R=I^N<)6EW7?NGE$@T&97;DP;('9^Z48U,:>1 MFR Z6R3@Z7.)_[I+Q&8ELPO.3KZ_!;>?LKJ'SJH$U#\R\JO_/"?.WAI2\YKH M-7R^,(7!YM%/A5 'P\./EQK-N0Z9F7-]M2R-4&1B7C N.(D#"?!?FPW=:RDY M&7$-/K ^V1/5[S@:K2WF8V8ATI" D8OR@Y*JT6-"@VJQZDF,*75SXB@':;:)I8J3&>C=^X_)\*#5<:1=<3V M!,P(J.O&>TF'52S$X]EU.OCC>?'.W&M0@RQ9&<'4[^HOJ;4IZM(>"6!2HZ++=:Y&H=1X^$715UF)#"MW&450'(AAJ\V$!%A/GP0E M@OO$4DLN7?A-H]1:UMZJ+7 ..*J;81&T#%E?J5 M#8U6-V)VK)7XI8CX2OJWAM"[+Q:FT*\S?H1!Q[$$>$[7)RLQD&%G&'M)5QYF M7 ),SYTQB^BKM:0$?+[25?9VYIIL;LRI[5PJ,MJ>2#<)8BFJ:*=GH.)%V&HO)<]H0?)QAXBZ M#O-H^G5JC\ #!7#5Q-_2#=<7QAN%%!Z]=9CMH<0JQ(@GOLK)&N'86\8[9?) M4F[T[(AU+ D\ IB5 .'X$--?U+,WP:Y6$;% =#3=$H'75/YL!Q,1(]M/E+E< M L#9>QMN[7=:KC"SM/[AG#@;8[#9E(##23F-,+7GH$\03 W=&W,W:0/YHMGFR3MU M_-9F"3!S[LS.DVMZ'?F_'W5JC7FK8B[\R85!H8NWY[-Z@M)>ND5R^KKHNOU% M9K,1KXRE;,Q*@/^Z2W0OCKW@#08E@-@.9CQ@E54)N'+SL9.N*3&CA#DO4VVC M'P3[T'B?>E2 T5K0M=M/J>M[SQK%.=.=AR3C( 5 M[]6:=^];V@2$KV5VLL"L!,!; TXUL1F][]P]/DO H3BCH-"0W85N) '5#SJ) MF1<\$;MJV!U]EZ5C$?35>]]51I'J,)6FWQ1>,>KZY[0B$Y:FTXL0(7"3EJ<5UR]H\@K[SV4+/SO?UK<'/G%9='XQ'E;\,#9L*6V,_$'H[,\JRS/53^8 M>LSZE@$;$J SB4IE:>66J?=W\HH,>L&X2PUN) '2WGZBJPONM#DSG-+RFQAI MF$:KHQ]86+G+2%BK&CI-S]JTM(LLK0(!0HF,I6UKUTJ C2@K&GDB :;GSFR, M.'*V>3$NB\:_6=%!O&59-QZYJC'-3P6V[U@1:=[&*XRWQ]*Y@!7&(4G#?4\: M=@-Y)0%$/,PH[XC.U[UN) ' N. DPB6PO6SC$V(X10C$" !WHZ=.W,^]=_\PU6= M+Y,K"7>:C4FHC1!;;'8FYNV;)0F0RI1_#4HD@H+8.!'FY/OKO]8HW"LHE/FW MGFT)"#MJ%&#SOL\)V\TXL<_E0$RI)6 R0J_YPA7RB/K.4W>(^'_H?$NK0!13 M5F:RVI-\E@! ^+\_N%P"S(3EV';NS/FD$8A=V/G+=EPCS&EL5KU+6O)GXS@? M>].QWZNYD0#=@(-M?)SG4,B>0O9ZQH'W]T!,.=$_U0\ZW4X"3+<#;.SGS.N/ MB(*W_V"L;5%I]^DUPU2:R$#,OX*WY'CZG;:T"D2QVOB09FPVPTMV/)< Z89( METM WVDR6J"_N(8#^P\JX]K.)Y8N]3L"4XY<*FKAN!DE549+4C\=++9R@)U* M^\_=HQ?Y;$$R9Q( G$FO)?KM/&O2:=?[JU)K?SEQFVC;SX=NLM$PMB5 9[*= M 2DRJ<9ZD>+*#F+7GMG8+>/3ZX=:GYEQX<;.3Z#'#P^:_[<+1KMRT+'OE 2P M;6QMD !O31=Y(H^#:%771H0:(*;,ADC+CI=22T4>=XCV,QH,0WA!=#IFZX0' M1\_V]::K[Y0$Z)1J@:>_"R5 -/EGLDEJC8WGSIQ,O8>27=[] K&B3JX?[GG3 GY^_Z2J]M:%' M2KB4 +!"Q"$UZ$:A1,:V!(P+3H(Y2%I^4T[)$S =U',)"LTEMA0--J=;)->Q M P<2 , (-/U=X.?#4(S-;BBXTU9XMPTZ8>6NPC]-BR*R?3#E&.,G!T?,CJ4_ M<;-YB(-@AG0HKL*6_$Z>S[5E"!V(*;>28);-L162+-OO0@GH.T=N%2FN5W&Q M"C1\DK*BT>42H!L(G_#TC[%W^9VI]=6T@F9ZM3 I=JP@^'MF73*6)$#WQD%YTMY^]H8--Q*@T9)16#8F\"M*JCJ8;8RTSVA43%N= M92DG$)Z)S"NVTZYK#] M_1WA$PGMO%SFI.8UL=2&M/PF&X^'/VH3VK@* M1$$X0A<957"WD !9R@V72( L_AK1$D5>.3>K0/*L4KY) $7S4T%T1FW([D+? M59GCODO^>%X\>)43EJ0&;DU9UZW^$J"BA%+J=![##X.D50!QC;L: EU,GK9S@*PA(:T#/6%_\=_E> M@!Z-5O@_2[F6 *^I6@FYIRE>M)<+"?",<<2(/(/)]J@ M/ZWL.9,#"9 L/XA/'$$0A(YH6BB7$B!+)'=SY)?+.(H%JFIZMQXM@B#(8*B? MOA1X^7$D 5Z^VEXR9%K\W1X.[+_PTQ7XK!$$04SIC MT[G8"$Z]@0\:01#$+&"<.9 60IIA^69-[F8 HP,UJDT^)01!$',HI7T@)UD M5P*\IH//3]Q7_,U.#B3 - P501 $H:-J[A!XS&9/ L#:$W?4]LH%7KZL3P'& M?,^?$\$(@B"\15G5)/",[4R)7$O9C<@S"91P'9\I@B"(+:CK&YVEA?!?*< MKNYXA0\401#$+M0M'<*/%S,H ?++9<0M9!>NL3T%Z#N=C8^2G[2]$-<_>EW] MH+/QB4"A'"18J_%Q=U=W+_U*MT@.Q0>]BTJK@VPONWH&S0EYJ/; 7[%4,6C^ MUP(9Y)3V&H4W2'J4<)%HJB6>/I? ;V>J/U5J+=167O?B49L0/EO/K-'J[C]\ M5531;DL#1%(%_*B:QE>0X%!CGA1B.G'($/J_=>MQY!$'Z\%++MCKY+O[@SZ@Y< M##M:,NCMP$H/FWD.,C_N$#G9D]#._3$5GGZGH38JK?ZWM2,PZ07-PV>?'\AY M&/Y^MB 9S+65_,FY#R$;U/_!U&/P(6##%9%EB001A#P?3#DV !,Q4<<3ZJA M+'-'I]3*CTTK:(9FAQZY!=,H^+>R_N6XX"0P[U#*4A%* L"VP^<"O:1&$,)' MAY( * *?FY\*QGV7_$E0(HYV=T?SO$L\9YLS$J#((\=YW[D<%NV_UY3^TCI\ M<'S&( & 4"(#NW$J];ZES(Y)@%BJ #,;?[D!W%?PSZUG-DB P8Z!$%C)#\8? M_&'(5MO415T!0 W;(LLLE:)+ -#ME3:"DS70* Z S]8[)E(0[A/_TW MJH7C0QR0 &E8E$ZI)FH3^6UF<0O@%&X!\!VZ!("["(8B+;_)4F;').!\5OT( MGTBI3+ELQ[51 ;&#+>R\E8#$G$:HO*+NI:7,*K46O/V+-QZ!Q/QRXC9U$;SQ MO_TS%80,RLKD2BOW LD;.>4(V,D!I_K0S8H.A[OQ1+)^PF+%AZ=34M4!F8LJ MVHGK/B$7)RQ)M52*+@'0)S +B,UNL)29D #0)N@BN4*- W[((,\J%4U89Y<$ MF*(52L%19\G^2S>>Q,?$?T "OEJ6UM0JR"EY\MF"Y+\&)?;)+1H*D( /IAR# MOX9$K4M;O\7$Y>G@9L.'PKMMD/GZW38KF4$"X!;@V'^^,,73[W1TAK59).4Y M-[1T@T=-N?&@+UXSSQV*J\@M>0)?6=^J/IM9][[/B1Z94@6E9L50C72,S8=O M05?8F!DF1-"VMA=BXCHTX,,Y%B^$,ZW LZRHJ84A)P(+8">B J M[3Y(,.3'T3[T4-4]EH3\)O (<$P"^LY<9LG^B[_;HU-K\ 'Q'VH[F-IG#-E= M^,IJ% W8_-5[KY?5/#>DT".WK$L 9:6+*_4.-IBLX;//PUS 2GZP5.]-/PN3 MAO&GP_=!#?;QLR4!)CN%"S>GC\N.,E2*4H"QB]*AC[L%O99OP4E 50: M\W7"\:0:C18'^]!%K>DOKI&L.R83#C/QTLGK T':XH]6M$$?MC+!Y(IU:]?$(N4@WS7W<)_KUPY8%C MW7@DH6I@/F)3U,W-"OU"4&J>T8(;S$1@"F!%'RD):'PB&#;S7-#F'.LFG9* MQ)S&0644&6)H>V2*ZU6]1]-!$< 4TT\!:+J$,&M0%%3TGS-O_ MV6C_W0GZ7L"@." !8-; ND(I*FT_H8_YM+*(;=@+H&JV[L:OVU_TC\5O%L]7 M["K\;$'RZ,"XHPE5U)6Q\Q.6_ZO 4EG0E_=FG#4T#!+(D^^J3,>ZL:E5+R@+ MP_-L<;9!<,&,_^V?J?2MBN,#X4\PL;)4RK 7 %,J4+==9^Y:N06Q%T!!G)Y MWC6HHV&L)O&BO;C^XUZP*@'4L@P19?KYPI0I*RU:6OIV\.+M^2-\(JVLYT__ M,1O:3WW.+VNEUCW:7[XY"35_T]4OEZ:9+0B&>L3LV+"CI?2+1P<\>8>LA8N1=\. M/A17 9\O%UL,ES65@)R!1;/)B;%8]%+%T=!><84,1J4PYZZ?+8.0M';,-W'#ER']\ M?J5:"\JRE+:0 B;=DE=?V]0%;:AK[J)??/:J!RXZO!8$9%Y_!$WZ:&X\3"B@ MK^(N-5C)# Y_4&CNJ(!8KUDQ\#-S!C/.>:6MT#SH$^I?4 WX=98V!2 ;9(8B MABOP8WU"+N(!L7<9%B7 RU=VX1KV,((@"&]A30*^558W8?7HQ]BJ"((A;P)P$>$N6']0(Q-BE"((@[@(C$B": MN%Y9W8R=B2 (XEXX*0'"\2&*_'O8C0B"(.Z(HQ+@+9JQI;^X!CL001#$?;%; M CSF2L.BU$^>8] 2* K;W M'DU7W6_!CD(0!!EZZ"7 RQ>LO7#L$M&T4,G*B-Z(%/GE,G5'%W8.@B#(T 8E M $$0A#W^7X ! 'L"K P-"F5N9'-T%LP(# @ M-C$R(#Q;KW@:*R M2G1)I(:D5/9^AA\,[$_L-^Z)2U)2E3P]1@-=%)G,C(S+B1.1?/?A4V2>QKMO M5G?O5JO(1&;U>!=%09B:$/_D*@F3($[#W&1QD"9E;E;[NW,.7I_$>3>8![;D\7\<8Y[[_^ 689G MC CQS$[C/69N1XQY\C&M=Y1W_$5!CWVHU3,O]6CH!>]7>1;>8\& Q2B=#?@B M2W+\P>ZC)$BJJJ+=A[-RO=B'UM[J*J^R(+S45<)[@2X2VDEAAKQ?B_?S&=K8>=OX@3[Z]^1$],&OZ+6?OD,"7N MQ7PO#I/DMI*RH.1M5T'VRY54P@LOE(1]L<%3NJ"]+ ^'H1?1,Z_=UY/=L0L4 M(E#FP2?);K+/VE_D>-3 N(EWG.!6\^"(!O04^/Y X97J0WAF9J MW9!NY$W&41"E9UU'ZO%II"[?-\UQ,+:F:1*OV1I2%RU7PK;6I[7U&=FT\LC? M'^JNWM2(C(T9^[TU424[H/46LB!\(LIH45J3=;+0*UKTH?8SS-C)'^Q$?F*! MS!O-IK7\VSS"P3*LF_+.Z>&>(P(BIA5)VW>;%CON;I@S3M(@#W&1%Q"[$@M= MV#.YMF>PFAY7@"F9+@7^((GB>#) O%35F81!XG39UR(/OF"MO:Q'ZQ9 MKLF.$/HH?R>S5*M\\!<4-!]^7!*:T+.5O\B@9 S@'S=V0N%2TD[2)"BJJGBU MD__SOP!Z.3P(/EHX'XWI77CFAP\_8FV/)('K>ZOEK=6CE/688);\>G59^+Q< ME+&29+>LH$E^OO,W0ZPT*A\+;[OH! MH'!O>H9 O/#=P^ZSK]= B+H3%XR@S^("7A*WO.)6VTU##0COCZ/Y[&$-\N[O M?8ZS/W[V3G3U^,;M\$,\> M#_#S$=\$AT]^B6D8J"2PZ6>#2,.*!\9/^'P_600:O?+9^_ #[E) 8+/TT'P/ M8>EB_L @^G/HAPEJ,(<=@9B=S'AD0\3>(T\(="TO@$8G4Y/7C=C)JFBQBN8O2H*4 M4[\[ =/;CI.OTVL).T+"*\V&A8))5*DY9WGJIR>:/(?OD)$2KR9L"(Q9(NI( MR1)UA":KY9R(TM>)Z$_>ZIY0KNGWZ[;#'#Z9V[RTT]9L[:$>\(R@KV[L1/J' M"2FQP*")-]:[EG;J,A!9&>*T#4:W&WB;") CW".H]+-_KTE-MRP"7;N2>&^N MBH2? [ '$) =&S_FI3Q3']AW*!MZO>C2X?1C/RA%Z6K1_9.=72"2[8>ZBBRR MQ_24KP_8/2Y'V;RB0Y5?6#EUTJ7RYK$;)S_'UFJ??&8-@E2S4?&#'#\GKTKP MIZL1QZ9#C/U^,9L[*5X9.W;T25WR!7%+.3&FR5G'H%(-V1PK7J7$F%-BSBE1 M_;COR*[-[KAI.W(0:/W ZG=CW68E<89!&%\I1]G)MB>RAR5)]"Z-S\\L.L@;)'G0&4VMI$I!S_QK%R24*4W6A<. M+-"U?BJ)LH0N2#8R\X!P, *=%4(S)G24H(N\QZ&6BX9C#\A7B1H9035&@<.4 M^_?PVCG#@HMV]F5&#DX$X75,DAB:!(6UZ-2)6JBZL% M-YBO=.(A(>!J SW4 MTS: '$7D?:/HIK.8]:YOGELW]@E2%G/% _8//_R3<*QCR$ $]/<,RI2+EY\H M \OFC(.GZAJB<[D;J/(.PZ+!3]W"X MK9A]@=YDVC-Z$T^A5<[H#3U53$:U/@!6[^W0P+O:_Y$Y! 'S\$JA"Q'O3$ZC MS&FRZ8^@!2T*CI=^V&U>VHW3Z[VQ[:1EVY:UBV)&JHI/O<%82W@8^6A:Q51+9;<8ZP7WKN"X5"&G94D59TK#YX+3E9YL)-0%$84. MF($'B_-/J@\2?<251.3!"^2"X44&M(QJ3S[7IUN?_N>D MLCY3_ 2B0.:$W U$4HO6A% MI9.!WA^MO+J@N^ >GNWT#BI9H(N\K9.0@\<\ZI[6D 7&@VWT>;V3OQ/W@)AT ME3KJL*W/TSJI&WN\7J"A,1'/PQ,0O90G!]YO1YSAWB+ M'^$JJTJ7$/I3>^8W;=?U)P#IR=XKTS';]FF[^.D(I)R4%RF/4DB7A@J%NM92 M8?4:SWE!]>IN(T'$*%M/9F\U$4W$AZ7_8^UF="4(92'N=#3'R;H,>X6*U;R$ M9B+3*&E!97W0'+35OTI>QA;8WXWJM1?X6#$1K93:!2Z#0<30.Z?#+'FE5\FS MT9QG_T/V1"RX-N=D8PZN&SE6X0,LR838C16<-/,- MG*A/ N78R#E_7>8GO2=I"OEIYH>O&R^"[U%4QA=]EYS!KO0V'"@$]WP3U(O_ MGN3/KC\@\]<-__A)'/PH;\CK,FR$SQN9%?N5T3T/V^N\@]QL91"0^>+%M4SE MWA^YXU/J!/*,/$CD:[L%W]GVXZ%UR5%GO5<99"V1\Z9UKKV^?_GH MF=^2 9,^%]4JJBF9B6N+MUO7_GDE">:/\I(O*]6XV-5XX257'?0NX1,?-&VG=\-Q:B#;< MM-%"E>Y[%C7O7)%.7/^#\KN"TS5!N4'@PB4O' >^) 61(P5'-C20;7V9J2:7#DYPZ=I$2KS@1;WOWL5Y;+$:$JK_9F8R) MN*5OEWM#\>(HR%,:>;U2Y!)8',6S:C1=9J1D3VC6U*_;P\"7_8YN(\]LR'@" M%C2>&(8TBY%S8>E^TQ[WT"']ON652&*D+-;2O*9\4M+LA-*X6.:7CM]915CITFY4SBM"#R$B<% MB&22(.NFVF/^[YKW=O19:LN=]*5ZI^U M^4RDC1M5S,I2[]Y\YRX_^U^+R-_(D(%[66U7G^PXWG"3M,!Z,0"$CKFJ+WIE M6H9" Q+J\JBOG,\NR$5.]O)(HJN?:VF&)9SM"Z]SK=GD=3/-&2(IU1! M'ZF@C+"U&9N&^M!NJ %RTC,M.XR"9)G'_!]5?<,&[$8J8B=1+>AR^;KW3.LY MPP]$&QY;1_"'=K?C0I>:0*-/ARXM91.8^CB:8:O&X[.B@A")'FU=??"U63Y) M/WJ0DYIQ4CE>6:#,*6U!I1 _^K(%JI3J-PP/D3(NHC5Q!F ,G%JMF@026\;? M6&/&&0!W;I.K>"Z]MUII:RWM^OXY]_UCU_>':907BWWXQ]5AZ.;8:&F& 4._ M7U/,&I=%DN2RDQ(Y(2)7_]=]KS=(!?0:L>+S"[,6G?C7OOSZ**_IA[ZKJ:U7 MRBD*>9,A"2-ARO2[@WKWX(Q$(]Z/^Y[V?0O:@>@IG8?%948E_!<\AL[CRI2' M1^3LYYC5?EGB^F5"4;@4P/+2U]%>6$.REXQ:4B+KV,)KX^CFKDN&IVR'NC?6 S;OMA6N@O.:Z:M%,9>4_. MBLG;6'#U5.KJJ;6=Z@5W.EU)P)YCJ!8DC @30.D$WC:VGJ8J..K'34*!&8I MFB;*(,EN 'UZ!OKSX3Q'0']2#Z['YK@CA^=YZ(N+,P5S?"9S77_:*I'+#>5( M1N&,TR:@$8Q83WL)+%*N.E)7=<2@PW1S],GY54N@IS?/?,A("J*']F!W;6?Y MC&+H*? A?K=IG;316^J\J2<43XX/FQ5W3O7+ *;$T!T%Z U?"XN@)-B*LR)X M^V7 :U<#Q%8QCTXH?EKM-*.+ >\QF.,JW':B^3BU*1W?HI/U&3@Q;E-7M MR( ^74!*,1)+M@>YS4]Z"^868.8R8]^1!BU M.Z9QA6-:@(Z77I[O^,7-W_C':';RN.;_-_P-"K5"I"DP7_UCA+D>N<>-?.J0!P9/\S=?AYU-K=3O40SK+'UQP.W)=V%D M:/,=8E_>JY/M6RJET[]_I-(+N --%DU&&7WC^ LTF;E-*2WJ^N[OGU8+N[,G M*0>$"?(W*99/>$PCIT.]8*4RO<*5BIEC>HG[+4QO_&JF I==5HUDQWIJ[$J^ M'R N!OP1$FW-(-G54EY\A?K+(PH@SQ\RJ[)!VA M(QT/]44*<[1BUS^Y/E=,=]XM]Y>9KM6V5\/WSO4*>S'(< M>WFE97<[\QNSDNOQ6;SR6[_0#F@JG<_8TX_9,/8'^93MW*;"W$CZTKWZ<&SG M[-S)Q4A%:>H%YC=R 6O CXWFG>[?V@!,.+HG[! B3#ZD@$N4KV<$4IXIU_G MZ5"5 L) 0H!C(E",@T M5C QAS)-%4PLH2H#BO*3@U-+HO4#7-ST0U(K2F+M[ "# "F^2!<#0IE;F1S M=')E86T-96YD;V)J#30@,"!O8FH-/#PO07)T0F]X6S @," V,3(@-SDR72]" M;&5E9$)O>%LP(# @-C$R(#%LP M(# @-C$R(#7!E+U!A9V4^/@UE;F1O8FH--2 P(&]B:@T\/"]&:6QT97(O1FQA M=&5$96-O9&4O3&5N9W1H(#0X,S,^/G-T*1$ETL\@R+Z69_0T[YGLW;P!9JIKQA")4 MO(! (I%Y\F0"WWS[H-7S=/??CW??/#YJI=7CX4[K($Q4"']\%8=Q$"5AIM(H M2.(B4X_'NV_NITS5DPITG$[U 431T519!F*@^S(%() M2% 4\"8."C6:NX,(GHK@$4L=J3*$X<,(/BN"(BX+%/D710U)5+EXO?L?+PK\ M?9Z&0>%]K.;J./3M/(R!^E OLU'WPSCX>XUO^VJ$JQRN?O1U&42>>H#[),C@ M_G\?_W@'EWD&0L$D]RR3C!/Q.'U#'47>.!S-._7IU#;FV [=\"S/J=O""]3? MZGEXDH?&CV&$444A]$_CW-!95L)ZW=;9M::R,@W"_Z0I;)KB!/9RA3.(45-) M&:3>9S\+ MD>_[F149!TFT461N%9FS&*KJ&_67JJ_\?1:4WK-?PK>H)^T=H<,(GO%=/ZOA ML%G(GH;+01Y\RZN9L]ICNYJIO9?ERCTQ@!RDG-07[\/]PQ?_G?J@?G8Q\B+( M_M-B:#!77HT"7.-7V6UBU9"P&NY! TU;]>H[,TXG@\K(O'INST8-/2O^?F&% MZB#6K%#X7FN[KGB%/8V@?2W_<25*U-RW"]@GW71M;_S4V]/[[TU-#T$I!?P< MC_*!M&U8+; (V=878BM[S",^CB1O0DN1>O/1P(@_^?LH17/XSM_#FW%6^AT^ M@KZ\OP[]_N'QIY_5>9: FG^USK,$#B/$!T_F">?;"%A P-?!7$1@GQ M\I,/"^EUYNSO2Q 8;3[RYA:6 BQ&P6*I/Y(=)1[K0<8.MV6,'9Q__BX;0=CBS&NS?C M7+6]FFRGDX*[^:6=5&]>)^4#M*,)%&6Y&H&VG3BS,P@),3IO-1FVV'KHJ>?# M,.(/C=/1)"R%'NSY M0&\@; !8>/5FS!WHL=ZT7)I6)DM2)Z+/-]Y0AF+(:$[#,JNN/;8^AI29%X3= M@YZ0[8EQ\^*!]:+YL#T.8T,C %V*LW#%:AO[RE(L#HP+VO^&K/_)QXZ[UIS! M>U.P-7Z\P\>*KPFF4IRR3BFT11C(?K.3UR=L"DM!7_?RN;Q[]3&0MEUW^1AA M/@,UMV!T;X;=EQN?D8DXV]M2HMA2(O@2U@$)#FBF[1<)"O@8ND/3P\N*6D"# MNCW1H*X-O8:E!_8#[XUC6/R2-&5^D&F[N;;'3 M.2M(L776T$;JQ%K:D7K6O) :W?\\=&>S4T]@?M5H%#I*!Q8'*W=L9].H>=@A M$$';>CCR<&BNUMITO(5HAI\]TD,)>!!&@5L 6LV#&I91#4__,,0Q)J?"T]@. M GR 11C4\M4(J/]+(Q >D]J8BGT\P:KJC*BT+LDWJ%9:KYNQD5P]EFPVEEN]&:52ZO3D@6 (8QT M&ZB'!0;&>(8@FW-TMTPUEY4)I0.)@Q+[0T3DT+MD'N0#ZFL_O(JN@0^46VW< M,KFEYP_&=OH*2[WT-9,:CN!LOVF07T9/!C!=%(6+GD!]U0!([J?$H",.,QA( M]RD&&4J%O('?31SL^-E%I(OD%K_ %@O128QT%"?P1W*I3:\+WG765L!>X?9, M'^)53U=H0R)88R@FGO$EK 4JOZ 0<=D<7/V)!CR2J/P1=X$V3B(@<=*.N6'J MG=CJ5FC ( ! ZV"A/0*9@@=/TH @S1*9"2V?KJSY)V3^*U\KKP#3Y6ME:66Q M<:3<>D* 23&-5FY'NS)S1,:8@E,)4&EEZH\#Z&,)V^Y0QV\JG,O9K4 M"5-#(,84'\ R535-R_'$\$PDF/,*KJB@S<;,7C7F#[ )+X;7E%0XK'OU#,WZ?EG9$+=*2'N3(V'?CA* M.N#P%)+C+2R7F]B]3&T//K &/,1D0FDBN+8>4%Z'I]*&I[_W1%8>8$R(UCYF M2P:LE4HI+29='>1TN+DN0>#+I5[,L9"_765R(B6R-<6%7@N+SYG;?2&Q9(.6!*T MWYT2@7D<)@F8@!WXN[9;K 3H5+B(U-S%Z0V?T1:?D5D,Q ,@B%U$=TP:=JRJ M2)J?$;L@?0D6F+VQ!]C,FD;+MRS:PG64#EJ@UQB8P%O=:RQ=N^?&97/%==D\M67ST>4N^>KW% 93+JF3T*/I;/1*"EN' M6#,C\N;" WE'4U'9%CV58EX#NN#^$D^:6:@JL1I\&=:E%)#JR!8#)=\9(813 M+[! /\@%IE\&TQ0.[%3#P5R/6&*![$Y'F S#M-!RX,M]W;5]6U?V Y@@HT\1 M9,EU('*AH[%AH:8O/>[$JHL>*9O*T!VF2?"VQAB#1!!-M3E++[P-,4X4@6RR M1!+)NJ S(7P\^WE >7\YM!C 6(GJ?, MX=!*B[JJR7QL6]8+6$52%C=* =J6 BSC0DYKN>XV?#B3$I0O0DNH713<8U%% M%OP]IB-[R-#;B;-S&[7G]HB3CT)'/Y#[I&GYQH1D[:+(KAT(V!C7W;%J#'+P M*-SLV)&EOIBJFU\N>,%"X;RKL'IXN<+1J65QF(#\N51W)RA M0)!B;(1]E/)<52=0GH4(,#>[= =86GB-@1GXQ4H<\$/^M<@@V5,CCV^7E&[N MIJT!%Y4O^,"&^\^E'9'62FV BA/0-U9Y)DOKXO@7MCR7)V#&D#G E!@;%S)L MQ00C(6Q$XW0UNI4TR(YJ%F]H9VBWJV#=L+ #S*D"!L'%U@K+4E2&>D^F1*ED MB H*-XSQK1')IH0N[*:$S6YX!X!R'.9>1P;=F$&GI H3WD)&*P3K)'L3ALI^ MXV&0^Q$88LV-^57@JE 750I;7+#:^P-,JF%&S34?Q[3;24T+5>(0"Z1PL:YY M&=WR%/)EZ5JJ1[VKYI"M4XZXG>VE%]358K=I6+D;-['P+4M9<%I,"LC6^!3I M\HI DE@27C"+WN;/4<@@3UF1JY;;S#FZW!;:)%!K/B8!9"U(D@@7=%*">EA8 MRBP[6:>1=C21/@&[\WEE\1II#F7.>,,[&(,4)9KV<'!?%42+()8G>"W9F!.EX<&(S?N%J M,3#^M-0UP[J9+-K$>MU[*2Q 3H>E8S+P(V4/"%"GSLR8JW"Q><^@N:$ISGLT.Z#+7^/:E/952>>/'AF[S(X'N\2 MD%);74M=>#9PF0+UA.C362/9Z3L1)$D=WHU5"6EY4-(3EU,8:3!011<*IPBR[8<)B/.O_C5:8 LZX,0)@ MP%!X4:UVBDC+6]&8"FVRUT3I@R0#E2@!PWS$FVN$PR\5Z&I=:,P^S20[-,YE MWFZ\4QE.N(G"?32B[L=J_&IFWLNI;9 ZS6O PI1*0GV8O-TC(\'MJ9PM2[DX MTI1[VXT$&'3@O9IULS -TN26A5#_Z16.H%& 7G U9R[LHCO+^M:U#3RQK#R[ M[VU;HE,/_8+5S$5J>V:GCO*"=2/42DW&]M/9X6;!>6W>V3NJN8=1MX:/;681<+ZBSI)FAN5PBBR ME4(N$/)>?"\;^5SP,S2IQ!6L*RD,.&X-M8-#9.0C7Z8TZ=6R=Y5_? Y53GS%'XY7VAVWDBP!/%2V %#) MJ%TLDY$T#W*BRAT*P@$^_6!!ZF6M1^BKFHUV!&$;Q=4])? Y33'WCL>6#A^ M^?SKX=/]O[_XJCH3;G0&R)5Z?7T-)JG#U,$%*QC.:RU"WURM.-Y6^'$^][B+ M8@M3T+O/+,+H"16&M%' M*VR(-6HGV51C *0L$.:GU+?MV9!10+["&U_^YFR*'>:FF29VXI<;PJ@&VO): MBRI(K'875CPL= 8#\B1T%:"E>!K#SBRY/@F7V*03H/O4536REF;!O?\.U%O3 M.<[);I5#KB-C[RD!>',<#B>SF>#;<'IUI&7=L6++=\?(=A<[(LDET&2VFVS= MSV.JCBR<';%%)YY;H/..=$=$NCFA6S=$*7 M7&-,8C$F<1CS*B= <*6RBPT[21#M 1*[0X& EWC7"J%*DF/.F\-Z6I1::E&J M E PK9R]1=4\"?16Q$-HE[B7;4O<8E #B,?U43R+.7.>'O:Q!YX_7\!!@!A M/0/:#0IE;F1S=')E86T-96YD;V)J#38@,"!O8FH-/#PO1FEL=&5R+T9L871E M1&5C;V1E+T9I"5 L) 0H9@H2 S*-%4S,H4Q3!1-+J,J HOSDX-22 M:/T %S?]D-2*DE@[.X P"G<2!=#0IE;F1S=')E86T-96YD;V)J#3<@,"!O M8FH-/#PO07)T0F]X6S @," V,3(@-SDR72]";&5E9$)O>%LP(# @-C$R(#%LP(# @-C$R(#7!E+U!A9V4^/@UE M;F1O8FH-." P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O3&5N9W1H(#$Y M-C8^/G-TY'"C_U^\^=J;5)59EZLM3(Z%YN7*%.#3/P. M4%R$8AB'$;D!A:D6>5JHPI8%@L ] !8L55;CX&;U45;=5MP$<>BV89BJ3\E: MI\K+(+I>].=M\WBA;W*U/Y_5I7%\-6T)AY3HQ*I=MWW]J.@222S%. MH' 7NFD4@#S*"=*[-KER#JVD'2J/NE%ET\'NN_D4 /"B# MC^&O R@6X9K4,U:O3+DX*UN/!Z@8SH@89-TD:ZL*.=2''4S@<)QXJNKJ,#X1 MX6^8UV#:.NSC%U&-8DC6!=H;3FKD7X=9#:#+X;D5YW'5;:(+<(1HHU*0M_)& M,<@'!)Q][WVA;'GG^^Q(KX_RK$K63I42]Y=@QTPVB*20/8YWB;: "95[57K2 M30,-SL^RU @/FUA7YJB;V"C_38"*#Z%H8U56H/P""]K/X)IU',T\3,";I9RN M@@!X,#9RV#9)#L\^ =9HQ%7 ZP#)A%O "N2XI(_@@Q(BFH(8H)%5E[11!![ M_@Y'13KU^R%!)4W@+:9Y*YJ]95DQ#=4VQ.VJX1//CK!O*45_ ?A8?$M;-#U) M&@(&)/WEJAKFM3QSU@][=M8Z4]Y;8FFF9UZ9I6N>7UZ";H=X/<9>@DMP[PS1 M(C$L3'I0.YWT4*9R@Q9W8!O'%O^BA\ HGN2=RDOVZ&<]]&)HNNJ:K1%&,!S@ M.H&AR%2!?'N$@8[X&2"E@;4Z>P0D.P+)Y@019JH,Y#Q'?G"2'69GAUER& 1- M?],%"*5;GD3G$:T<42:3<14Z#X,2CLE?*4PS"9D&-\GD!1+(PP.E&_[8DF1\ MB7)Q71C%3:+SR,Q,#NTVOC?;$,F IW">E-/#T$%@<511$DH,?1@7'!;GEY&"J6 MCO3GZ0URU\]A.4<=!66UC^\'^LB+R:J0,$?Q"N-?MEO>J.GP+4:].%,?T$:E M5$_(=X<1*D4IP>%0TU P#''_MB&U==RJ&\,Q),& ]T,2PF+AA=^!&P;WN ;? MZARIHM$M@!XJ!$;Y*9\XY5.TL071_^,3."RE5@LD6OCDZ)*[,'Q+/M'R/"#_ MM(QEHS\% Q)OZ:$0/H+QI5C,#['X(QA_(A;)/W,8NID9CL+0W ]#)\6+ M:FP0OJ?( W',FPFU'\2*&)B>2(1U\X"TR&535^+G1 /C)1 !ODQAZ%AG%25Z M?NVJ5KQ)-*9/BDDCMT02_DI4H?X!4#$12N6TOA^-QL8C:QN;"6J5!) )"W(= M0!MJGLF4+GATM%BDT0]CM$Q/N&OL=$YE< \^0") 5&M=^J]F\$RE5&.!<=H= MG96ZV5DXFJE#&#CW8?L#$,!_6KX!KV"2.D4ADP+'#*;SAX"^0"&#;:*G1?=0 M/:(SENL!W%;..85YH[&%2M"63!PF/--'8Q5^-^ROJC7R0,N7W =!#$!#O6@M M76S79@,$ZLV,O.9$'5KQ"FP"0>2XPF*.)3H7Z&7Q(0R)YX3N*/7A2\,OX7RD M.B!^ LS829Z_>C+WH5";2YL](,+C,M;-#-1WV4K=RU=UQ-F-G+("U;,ET9BG M2$^](!ID6K!+@7&4T:$-YJY;'A40-M!4?J9[T-P]N,)B$?XJ]V ;ZAY<7N(] MP\]>+HZG+>X*R3%3@.7R8PG)YT214PEY/X5J&^O=6SBOYE)14(V/]?G XF.2 M4NR25@Q+%F3U(IJOF,WG[YD/DKXU_KZ/CK%.(^K%*+VVK>@YRB?FR%7@:!F@ M*!:Q#AQ/5((&JZ+]W%7166K6W'Q=6!; ML[Y#VA>P)52[>OIVUA8OGD!&:*T6MZ[Z>+?#Y:_IHN:@NF-3-G'_W8E?0_?/ MDLMQO5UN_",=X1V);;ZYZX_6<10O,XX:9FA]B298 G:!)JFHW'W=\0LVY/2^ M)VDUJU]<2._00Q93'BJB+R&/T#T.B\:DP'C%O'"1#J'S51;J9EG"9XB9J)9A M?Y1_8B7"BQ>Z$0VPQMSWC)K/FCI3^@Y7"GH&5<]#,=LJFIJ<-*++.#4=+UB3FG?GS0DK&TP0 M8&E=IF9A9;[D?I2[IKX* .X9A!X8.)/X_P,O^VE?X<;08DQX;D7.S.C? %#\ M=F)9PX^W?E8YAJHC=04J0U641O$J7BS4:5"&,^ UU/7#9O6? , "NLS"PT* M96YD7!E+UA-3"]4>7!E+TUE=&%D871A/CYS=')E M86T-"CP_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZDY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T M82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N-"UC,# V(#@P+C$U.3@R M-2P@,C Q-B\P.2\Q-BTP,SHS,3HP." @(" @(" @(CX*(" @/')D9CI21$8@ M>&UL;G,Z&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN&UL;G,Z9&,] M(FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT&UP M.D-R96%T941A=&4^,C Q-RTQ,BTQ,50Q.3HQ,3HP-2TP-3HP,#PO>&UP.D-R M96%T941A=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,3&UP34TZ1&]C=6UE;G1) M1#YU=6ED.F(T9F(S934X+3AA9&4M-#&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DEN#I3;W5R8V5-;V1I9FEE9#X*(" @(" @(" @ M/'!D9G@Z0V]M<&%N>2\^"B @(" @(#PO#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"CP_>'!A8VME="!E;F0](G7!E+T]B:E-T;3X^L*[?T,B(@]QC]/2X M'Y326^JX#+V)%0;_@UK(\G&N] Y3'>32L4=JPK'O=M3Z2LWG+P$& )<52:T- M"F5N9'-TQX%R.+S N0SN0X/\* MXDX'$6) 4]1O@228X00CB&!@!!),_\%<@ # [B##P-"F5N9'-T